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ABSTRACT 
DIANE GAIL CARNATHAN: Dendritic cell regulation of B cells 
(Under the direction of Barbara Vilen) 
 
The innate and adaptive immune responses protect from autoimmunity during infection 
through B cell tolerance mechanisms.  We previously showed that during innate immune 
responses dendritic cells (DCs) and macrophages (MΦs) repress autoantibody secretion 
in part through their secretion of soluble factors (IL-6 and CD40L).  Herein I describe 
that DCs from lupus-prone mice are deficient in repressing autoreactive B cell coincident 
with their inability to secrete IL-6.  This defect results from defective Toll-Like Receptor 
signal transduction. 
   
We further describe that DCs repress innate and adaptive immune responses independent 
of DC/MΦ-derived soluble factors.  We show that DCs display endogenous nuclear self 
antigens and affect B cells responses as evidenced by upregulation of CD69 expression, 
induction of IκB phosphorylation and destabilization of the BCR. Despite evidence of 
stimulation, DCs inhibit BCR-derived signals and LPS-induced Ig secretion in 
autoreactive and naïve B cells suggesting that DCs regulate B cell responses independent 
of self-antigen. 
 
 
 
 iii
To Paul 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv
ACKNOWLEDGEMENTS 
Many people have contributed to my educational experience with invaluable teaching, 
mentoring, and advice.  I would like to thank Dr. Barbara Vilen for encouraging me to 
apply to the program.  She has been instrumental in my development as a scientist, in 
particular, in improving my ability to critically examine my data.  I am grateful to my 
committee members, Dr. Stephen Clarke, Dr. Janne Cannon, and Dr. Glenn Matsushima 
for their time, ideas, advice, and support.  I would also like to thank the Flow Cytometry 
Core, in particular, Dr. Larry Arnold, and the Microscopy Services Laboratory, Dr. 
Robert Bagnell, for their time and technical expertise.  I would like to acknowledge Patty 
Cogswell, who made important contributions to our MRL/lpr study.  Our collaborators, 
the Clarke Lab, give great insight during our lab meetings, share their reagents and time.  
In particular, Kara Conway is extremely helpful and always cheerful.  I would like to 
thank past and present members of the Vilen lab, Dr. Mileka Gilbert, Dr. Michelle 
Kilmon, Jennifer Rutan, Nikki Wagner, Dr. Jin Kim, Dr. Michelle Borrero, and Dr. 
Stephanie Carmicle-Davis.  They have taught me so much about both science and life.  
They have been great mentors and friends.  The undergraduates, Bianca Trollinger, 
Jackie Hyseni, Christopher Hilliard, Carlos Rodriguez, and Byron Brower have been 
great fun to mentor and are a very talented group of young scientists.  
 
My family has been extremely supportive in this process and I could not have 
accomplished this without them.  My parents have encouraged me throughout my life in 
 v
whatever decisions I make.  My sisters and their families have also always been there for 
me and have cheered me on.  My in-laws, Chip and Jane, are very helpful in my career 
and life choices.  Finally, I would like to thank my husband, Paul, for inspiring me, 
understanding me, and always being there for me.  I appreciate all of his love and 
encouragement.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
TABLE OF CONTENTS 
LIST OF TABLES……………………………...………………..……………………….ix 
LIST OF FIGURES……………………………………………………….………………x 
LIST OF ABBREVIATIONS………………………………………………...…………xii 
 
Chapter 
I. Introduction………………………………………………..…………………..1 
Systemic Lupus Erythematosus…………………………………………………...2 
Murine Models of SLE…………………………………………………………....4 
Fc Receptors and SLE…………………………………………………………..…6 
Complement and SLE…………………………………………………………..…7 
Toll-like Receptors and SLE………………..……………………………………..8 
Cytokines and SLE………………………………………………………………11 
B cells and SLE…………………………………………………………………..12 
Mechanisms of B cell Tolerance…………..……………………………………..15 
B cell Tolerance to Sm Murine Models 2-12H and 2-12H/Vκ8…..…………….17 
Dendritic Cells and Macrophages and SLE……………………..……………….18 
DC: B cell Interaction…………………………………..………………………..21 
Model for DC/MΦ-mediated B cell Tolerance………………..…………………21 
II. Dendritic cells from lupus-prone mice are defective 
in repressing immunoglobulin secretion…………………………..…………22
 vii
            Contributions…….……………………………………………………...………..24 
Abstract………………………………………………………………………..…25 
Introduction………………………………………………………………………26 
Materials and Methods……………………………………………………...……29 
Results……………………………………………………………………………33 
Discussion…………………………………………………………………..……42 
III. Dendritic cells and macrophages repress innate and adaptive B cell 
responses coincident with the display of nuclear self-antigen…...…..………57 
Contributions…………………………………………………………………….58 
Abstract………………………………………………………………………..…59 
Introduction………………………………………………………………………60 
Materials and Methods……………………………………………………...……63 
Results……………………………………………………………………………66 
Discussion……………………………………………………………………..…74 
IV. Discussion……………………………………………………………………89 
 
References……………………………………………………………………………..101 
 
 
 
 
 
 
 viii
LIST OF TABLES 
Table             
2.1.The frequencies of splenic and myDCs and MΦs are not  
diminished in MRL/lpr mice…………………..……………………………………49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix
LIST OF FIGURES 
Figure                      
Chapter II 
2.1. The distribution of splenic myDCs and MΦs are comparable 
        between B6 and MRL/lpr mice……………………………………………..48 
 
2.2. DCs from MRL/lpr mice fail to efficiently repress 
        Sm-specific Ig secretion…………………………………………………….50 
 
2.3. DCs from MRL/lpr mice are defective in IL-6 secretion upon  
       TLR4, 7 and 9 stimulation, but not upon TLR3 stimulation………………..51 
 
2.4 MyDCs from B6 and MRL/lpr mice have similar levels of  
      TLR4 surface expression and no difference in survival……………………..52 
 
2.5. DCs from MRL/lpr mice show a decrease in synthesis  
       and ability to sustain IL-6 mRNA levels……………………………………53 
 
2.6. DCs from MRL/lpr mice fail to activate NF-κB and AP-1…………………54  
 
2.7. TLR4-stimulated DCs from MRL/lpr mice are unable to 
       sustain IκBα phosphorylation……………………………………………….55 
 
2.8. In addition to IL-6, other soluble factors regulate autoantibody secretion….56 
 
 
 
Chapter III 
 
 3.1. Soluble Sm and apoptotic cells fail to negatively  
                   regulated Sm-speficic B cells………………………………………………79 
 
 3.2. BMDCs, BMMΦs, and CD11c+ splenocytes display surface Sm…………..80 
 
 3.3. BMMΦs and BMDCs display surface histones and DNA………………….81 
 
 3.4. Nuclear, but not soluble, self-antigens are displayed by  
             DCs and MΦs, but not lymphocytes………………………………………...82 
    
3.5. Coculture of DCs and B cells leads to B cell activation………...………..….83 
 
 3.6. DCs do not induce BCR-mediated signal transduction  
             in Sm-specific B cells…………………………………………………….…84 
 x
. 
 3.7. DCs repress LPS-induced Ig secretion by autoreactive B cells 
             by an antigen- independent contact dependent mechanism………..………..85 
 
 3.8 Sm-specific B cells recognize self-antigen and destabilize their BCR………86 
 
3.9 DCs repress BCR signaling upon anti-μ stimulation……………….………..87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi
LIST OF ABBREVIATIONS 
 
Abbreviations 
ANA anti-nuclear antibodies 
APC antigen presenting cell 
Ars p-azophenylarsonate 
ASC antibody secreting cell 
B6 C57BL/6 
B6.lpr B6.Faslpr
BCR B cell receptor 
BLys B lymphocyte stimulating factor 
BM bone marrow-derived 
CM conditioned medium 
DC dendritic cell 
DRB 5,6-dichloro-1- -D-ribofuranosylbenzimidazole 
FcγR Fcγ Receptor 
FO follicular B cells 
HEL hen egg lysozyme 
IC immune complexes 
ICOS-L inducible costimulator ligand 
IFN interferon 
Ig immunoglobulin 
ITAM immunoreceptor tyrosine-based activation motif 
 xii
ITIM immunoreceptor tyrosine-based inhibitory motif 
LPS lipopolysaccaride 
MΦ macrophage 
MRL/lpr MRL/MpJ-Faslpr
MRL MRL/MpJ 
MyD88 myeloid differentiation factor 88 
MyDC myeloid dendritic cell 
MZ marginal zone B cell 
NZM New Zealand Mixed 
pDC plasmacytoid dendritic cell 
RNP nuclear ribonucleoprotein 
SLE systemic lupus erythematosus 
Sm Smith protein 
sn small nuclear 
snRNP small nuclear ribotnucleoprotein 
SOCS suppressor of cytokine signaling 
Tg transgenic 
TLR toll-like receptor 
Yaa Y chromosome-linked autoimmune accelerator 
μm μ-heavy chain
 xiii
CHAPTER I.  INTRODUCTION
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systemic Lupus Erythematosus 
 
Autoimmunity is characterized by the breakdown in tolerance mechanisms that control 
the autoreactive lymphocytes.  Systemic lupus erythematosus (SLE) is a chronic form of 
autoimmune disease that results from the production of antibodies to a wide array of 
cellular autoantigens including phospholipids and the nuclear components DNA, 
chromatin, RNA, Smith (Sm) and nuclear ribonucleoproteins (RNP) such as Ro and La 
(1, 2, 3).  The concept of epitope spread, or the ordered emergence of autoreactivity to 
multiple autoantigen epitopes, has been proposed as a mechanism for the development of 
disease.  This hypothesis was confirmed by clinical data indicating that loss of tolerance 
to phospholipids and anti-nuclear antibodies (ANA) occured first, followed by activation 
of Ro, La, DNA specific B cells and finally by anti-Sm and RNP (4).  These antibodies 
form immune complexes (IC) that deposit in various tissues, leading to inflammatory 
diseases like glomerulonephritis, vasculitis, dermatitis, arthritis, and nervous system 
disorders (5).  The cause of SLE is unknown, however, a combination of genetic and 
environmental factors are believed to play a role.  For instance, hormones are thought to 
influence the disease and its onset because SLE disproportionately affects women at a 
ratio of nine females to one male.  Many susceptibility genes have been identified 
through the study of lupus-prone animals and patients with SLE.  It is thought that around 
30 different genes contribute to the pathogenesis of this disease (6).  There are a variety 
of manifestations of this disease which complicates its diagnosis.  
 
The anti-Sm antibody titer is a key diagnostic tool for SLE (2).  Sm and RNPs are 
composed of small nuclear (sn) RNAs that are rich in uridylate and when associated with 
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proteins make up the small nuclear ribonucleoprotein particles (snRNPs) (7).  snRNPs 
form the spliceosomal complex that removes the non-coding RNA from pre-mRNA (8).  
The response to an unknown nuclear component was initially described in 1966 from the 
serum from a young SLE patient, Stephanie Smith (1).  The response to Sm is of 
particular interest because it is unique to SLE, however, not all patients diagnosed with 
the disease have this response (2, 9, 10).  Interestingly, the presence of these antibodies 
are associated with renal complications and increased disease activity and severity (2, 9, 
10).  The anti-Sm response is an essential aspect of the diagnosis and understanding of 
SLE. 
 
The pathogenesis of SLE is complex and largely unknown; however, it is hypothesized 
that apoptotic cells play an important role in the disease.  These cells display nuclear 
antigens such as dsDNA, nucleosomes, histones, and Sm on their surface and provide a 
ligand for autoreactive B cells and possibly toll-like receptors (TLRs) (11, 12, 13, 14).  In 
murine models, studies show that an acculumation of apoptotic cells leads to autoreactive 
B cells activation (13, 15).  In SLE elevated levels of apoptotic cells have been described 
in blood and bone marrow (16, 17).  Additionally, dysfunction in the uptake and 
clearance of apoptotic cells has also been implicated in the disease (18, 19).  
Interestingly, a study of non-autoimmune mice immunized with antigen from apoptotic 
cells resulted in development of SLE by the epitope spread model (20).  This increase in 
available antigen could contribute to the loss of autoreactive B cell tolerance in patients 
resulting in serum ANA titers and disease.     
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Murine models of SLE 
Murine models are utilized to study the pathogenesis of SLE.  These models can be 
divided into three categories: engineered models, congenic models, and mice that 
spontaneously develop lupus-like disease.  Genetically engineered mice eliminate genes 
that encode for components of the immune system thought to be involved in SLE. 
However, because the entire gene is eliminated, other possible phenotypes of the deletion 
must be considered.  Thus, gene knockouts may not reflect actual mutations that occur in 
SLE patients.  There is a wide variety of molecules involved in clearance of autoantigens 
that are of particular interest.   For example, mice deficient in DNase1, or the 
complement components, C1qa and C4, display SLE symptoms such as ANA and 
nephritis (21, 22, 23).   Mice that are deficient in cytokines are important to assess their 
ability to regulate the disease Lupus prone mice deficient in IFN-α and TGF−β, have 
exacerbated disease indicating that it has protective effects, however, mice lacking IFN-γ 
have a reduction in symptoms (24, 25, 26).   Mice that lack molecules, such as Src family 
kinases, FcγRIIb, and CD45, important in regulating B and T cell signaling also develop 
SLE (27, 28, 29, 30).   Congenic models provide a tool to isolate individual susceptibility 
loci and understand their contribution to the disease.  Of interest, the Sle1, Sle2, and Sle3 
susceptibility loci were discovered in an inbred model of SLE, NZM2410 (30, 31, 32, 33, 
34).  Each of these loci confer unique contributions to the onset or manifestations of 
disease and are influenced by other loci.  Sle1 on the C57BL/6 (B6) background has a 
strong anti-chromatin response to the H2A/H2B/DNA subnucleosomes, however, the 
mice do not develop disease (32).  Adoptive transfer experiments demonstrate that the 
loss of tolerance by B cells to chromatin is mediated by Sle1 expression (35).  Sle2 mice 
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has hyper-reactive B cells and an increase in peritoneal and splenic B1 B cells, in 
contrast, on the B6 background they do not have an ANA titer (31).  The Sle3 loci in B6 
mice, confers activated T cells with reduced apoptosis and the development of 
autoantibodies (33).  When mice are generated that express both Sle1 and either Y 
chromosome-linked autoimmune accelerator (Yaa) or the FASlpr, glomerulonephritis 
develops more rapidly (36, 37).  From the BXSB lupus-prone mouse other loci have been 
identified.  Bxs1, Bxs2/3, and Bxs1/4 are all important in the development of nephritis 
(36, 37, 38, 39).   BXSB/Yaa mice exhibit accelerated onset of SLE in males on an 
autoimmune background (40).   The Yaa gene is associated with monocytosis 
characterized by an expansion of CD11c-expressing cells (41, 42).  The increase in 
monocytes correlates with an increase in production of autoantibodies (43).  B cells in 
these mice have increased TLR7  expression due to a duplication in the gene encoding 
that receptor (44).  New Zealand Black crossed to New Zealand White (NZB x NZW) 
mice present with lupus-like symptoms, but also have other autoimmune diseases (45).  
Closely related to this background are NZM2410 mice.  In-breeding between the progeny 
of the NZB x NZW formed the New Zealand Mixed (NZM) mice (46).  These mice are 
particularly useful because they are homozygous at all loci and both males and females 
develop lupus symptoms at a young age (47).   All of these mouse models can be utilized 
to study the immune dysregulation that occurs in SLE.  
 
Another spontaneous murine model, MRL/lpr, has an autosomal recessive lpr mutation, 
which results in a loss of function defect in Fas(48).   Signaling through Fas initiates 
apoptosis, therefore, its disruption leads to an increase in survival by lymphocytes (48).  
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Defective Fas results in aberrant T cell selection in the thymus and increased lymphocyte 
survival in the periphery, which contributes to an expansion or persistence of autoreactive 
cells (49, 50).  Because of their predisposition to autoimmunity, the MRL/lpr animals 
spontaneously develop an increased ANA, glomerulonephritis, lymphosplenomegaly, and 
joint and skin disorders.  Furthermore, approximately 25% of the mice develop an anti-
Sm titer, which is similar to the response in SLE patients (3, 51, 52).   This murine model 
of lupus is particularly useful because many aspects of their disease development and 
symptoms mirror that of humans.   
 
Fc Receptors and SLE 
Fcγ receptors (FcγR) play an essential role controlling the immune response and loss 
results in autoimmune disease.  Increased autoantibody production leads to the formation 
of IC leading to inflammation.   FcγR bind to Fc domains of immunoglobulin (Ig) G 
(IgG) with varying affinities and promote the clearance of IC.  The activating receptors, 
FcγRI and FcγRIII on antigen presenting cells (APCs) bind to monomeric IgG and IC 
containing IgG and enhance the autoantibody response by influencing the epitopes that 
are presented (53).  Binding of chromatin-IC by FcγRIII on dendritic cells (DCs) induces 
secretion of B lymphocytes stimulator (BLyS), a TNF family member associated with 
lupus (54, 55).  FcγRIIa and FcγRIII are essential in the transfer of IC from erthrocytes to 
macrophages (MΦs) and for engulfment of these complexes (56).  DNA-containing IC 
activates plasmacytoid DCs (pDCs) through FcγRIIa and the toll-like receptor 9 to 
secrete the proinflammatory cytokines IFN-α and IL-8 (57).  The downregulation of 
activating FcγR results in decreased inflammatory response (58, 59).  FcγRIIb is an 
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inhibitor of B cell signaling and can also suppress autoantibody production by the B cell 
(60).  Deletion of the FcγRIIb gene in C57BL/6 mice causes an increase in IC, 
autoantibody production and lupus symptoms (27).  Restoring this receptor expression by 
retroviral transduction reverses disease (61).  Studies show that the expression of FcγRIIb 
on germinal center B cells is reduced by ten-fold in autoimmune-prone mice (NZB x 
NZW) F1and expression is decreased on memory B cells in SLE patients (62, 63).  This 
defect was directly linked to the failure to downregulate calcium signaling in B cells (62).   
In support of a role for dysregulated FcγRIIb in SLE, a polymorphism (FcγRIIbT232) was 
found to exclude the receptor from the lipid raft resulting in aberrantly activated B cells 
(64).  The expression of FcγR on DCs in SLE has not been studied, however, FcγRIIb on 
non-autoimmune DCs captures IC and recycles them as intact complexes back to the cell 
surface to activate B cells (65).  Thus, FcγRIIb can provide a source of antigen to 
autoreactive B cells.  The role of FcγRs is important in the clearance of IC and the 
inhibition of BCR signaling. 
 
Complement and SLE 
Another molecule that has been implicated in SLE is complement.  Apoptotic cells can 
activate the complement cascade leading to complement molecules then depositing in 
sites of inflammation.  C1, C4, and C3 bind to IC to maintain solubility for clearance; and 
CR4 and CR1 transfer IC from erthrocytes to macrophages for engulfment (56, 65, 66, 
67, 68).  Defective clearance of apoptotic cells or IC, results in acculumation and they 
become immunogenic.  In humans, a homozygous complement deficiency in C1q, C1r, 
C1s, C4 or C2 predisposes those affected individuals to develop SLE (69).  MΦs from 
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patients are defective in the clearance of apoptotic cells because of decreased amounts of 
C1q, C4, and C3 in their serum (18).  C3aR is essential in the development of nephritis 
and treatment with an agonist in lupus-prone mice ablates the inflammatory properties of 
this receptor (70).  Mice that lacking C1qa or C4 have increased ANA, apoptotic cells, 
IC, and develop glomerulonephiritis (22, 23).  The increase in production of antibodies to 
C1q and decrease in the levels of C1q is found in patients with the SLE and correlates 
with an acquired C1-inhibitor deficiency (71, 72).  The binding of C1q to apoptotic cells 
that are not eliminated results in the production of autoantibodies to this complement 
component (69).  Elimination of C3 in MRL/lpr causes no change in ANA but an 
increase in IC deposition in the glomeruli (73).  MRL/lpr mice deficient in C5aR have 
reduced disease, anti-DNA titers and Th-1 responses (74).  Complement is implicated in 
B cell development through the expression of CD19 and CD81.  These receptors could 
bind to apoptotic bodies facilitating the ligation of autoreactive B cell receptor (BCR) and 
resulting in deletion.  A deficiency in this mechanism would cause autoreactive B cells to 
escape tolerance (75).  Because patients who lack components of complement pathway 
develop SLE, it can be concluded that complement is essential in the maintenance of 
tolerance.   
 
Toll-like receptors and SLE 
One way the body can distinguish an invading microbe during innate immunity is the 
recognition of pathogen-associated molecular patterns.  These components are conserved 
elements of infectious agents identified by TLRs.  Eleven TLRs have been identified and 
they recognize a variety of pathogens such as viral RNA, CpG DNA, and other 
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components of bacteria, viruses, or fungi.  In particular, TLR7/8, 9 and 3 recognize 
ssRNA, unmethylated CpG DNA, and dsRNA respectively.  In response to microbial 
stimulation the TLR initiates signal transduction that activates both the innate and 
adaptive immune responses in order to quickly respond to infection.  This stimulation 
results in the production of inflammatory cytokines, chemokines, anti-microbial factors, 
proliferation and upregulation of costimulatory and adhesion molecules.  Activation of 
the innate immune system through TLRs can induce an autoimmune response (76, 77, 
78).  Lipopolysaccaride (LPS), a TLR4 ligand, augments an immune response of normal 
mice to apoptotic antigens (20).  It has also been shown that immunization of lupus-prone 
mouse models with either unmethylated CpG DNA or polyinosic polycytidylic acid RNA 
(ssRNA), cause exacerbation of the disease symptoms (79, 80, 81).  This data indicates 
that stimulation of the innate immune system through TLRs might initiate or exacerbate 
SLE. 
 
TLRs are important in both the regulation and the development of SLE.  A common stop 
codon polymorphism of TLR5, that recognizes bacterial flagellin, is associated with 
protection from lupus symptoms supporting a role for infection in the development of 
innate immunity (82).  Females with SLE produce higher amounts of IFN-α compared to 
males in response to TLR7 stimulation (83).   Genetic abnormalities in TLR7 have been 
implicated in the skewing of autoreactive B cells to respond to RNA-associated antigens 
and the aggravation disease (44, 84).  Lupus-prone mouse models that lack TLR7 do not 
display symptoms of disease, in particular, these mice failed to produce antibodies to 
RNA-containing antigens (85).  In contrast, lupus-prone mice that are deficient in TLR9 
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demonstrate exacerbated disease (85, 86).  These results indicate that TLR7 promotes 
disease and TLR9 regulates it.  However, the role of TLR9 in SLE still remains 
controversial as some studies indicate a pathogenic role.  SLE patients with active disease 
had an anti-dsDNA titer and increased proportion of plasma cells, memory B cells, and 
monocytes that expressed TLR9 (87).  Further, in lupus-prone mice TLR9 and myeloid 
differentiation factor 88 (MyD88) is required for class switching in anti-DNA B cells to 
pathogenic IgG2a and 2b autoantibodies (88).  Therefore, the role TLR regulation and 
dysfunction in SLE remains to be elucidated.   
 
The primary role for TLRs is to recognize foreign antigens, however, they interact with 
nuclear self-antigens as well.  Because of abnormalities in the clearance of apoptotic cells 
and the increase in immune complexes in SLE patients more antigen is available to the 
innate immune system.  pDCs are activated to secrete IFN-α by IC containing either 
mammalian DNA-IC through TLR9 or RNP-IC through TLR7 (89).  DCs are activated 
by the co-ligation of FcγRIII and TLR9 by chromatin-IC to produce the proinflammatory 
cytokine TNF-α (55).  pDCs can bind to DNA-IC through TLR9 and FcγRIIb (90).  The 
regulation of autoreactive B cells by stimulation of both the BCR and TLR has also been 
characterized utilizing B cells from rheumatoid factor mice (91, 92).  Studies show that 
autoreactive B cells are induced to proliferate by the dual ligation of DNA or RNA-IC to 
both the BCR and TLR9 or 7 respectively (91, 92).  It is hypothesized that the binding of 
antigen to the BCR or the FcR, leads to endocytosis of the antigen and provide a 
mechanism to present the antigen to the TLRs located in endosomal compartments.  The 
ability of TLRs to be cross-reactive with mammalian nuclear components may result in 
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functionally ignorant, autoreactive B cells secreting autoantibodies because of 
costimulation through the TLR (93).  This cooperation between the two receptors may be 
one mechanism to break tolerance to nuclear self-antigens. 
 
 
Cytokines and SLE 
The aberrant production of cytokines, important in regulating immune functions 
contributes to SLE.  Interferons (IFN) are increased in lupus patients and have been 
shown to affect the pathogenesis of SLE (94).  Lupus-prone mice that are deficient in 
IFN-α (type I) have exacerbated disease, however, mice lacking either IFN-γ (type II) or 
IL-4 do not develop disease or have a reduction of symptoms (24, 25).  Studies show that 
IL-21 promotes autoantibody production in MRL/lpr mice (95).  MΦs from lupus-prone 
animals are defective in secretion of TNF-α, resulting in reduced IL-1 and IL-6 
production(96).  MZ B cells from lupus-prone mice produced IL-10 in response to CpG-
ODN, inhibiting the production of IL-12p40 and IFN-γ in response to TLR9 stimulation 
in other splenocytes (97).  Patients with active SLE and some murine lupus models have 
increased levels of IL-6, and anti-IL-6 treatment in mice reduced the production of anti-
dsDNA antibodies (98, 99).  It is not apparent how each cytokine abnormality contributes 
to SLE, however, these molecules clearly play a role in the broader dysregulation that 
results in the disease.  
 
DC/MΦs secrete a variety of cytokines to affect the regulation of the immune system.  
Many of these molecules are typically thought of as proinflammatory, however, they also 
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have the ability to be repressive depending on the target cell.  DCs can promote B cell 
growth and differentiation by secreting IL-6 and IL-12 (100).  Further, virally-stimulated 
pDCs secrete IL-6 and IFN-αβ activating naïve B cells acutely stimulated with antigen to 
secrete virus-specific Ig (101).  Evidence indicates that polyclonal stimulation of DCs 
results in IL-6 secretion, which relieves the repressive effect of T regulatory cells to 
allow T cells to be activated in the antigen-specific adaptive immune response (102).  
Other studies show that IL-6 and CD40L repress Ig secretion by LPS-stimulated, 
chronically antigen-experienced autoreactive B cells (103, 104).  These studies indicate 
that cytokines have multiple roles in the control of the immune response.  Further, the 
regulation of cytokine production by other cytokines promotes a balance in the immune 
system, and their dysregulation results in the development of autoimmunity. 
 
 
B cells and SLE 
B cells are key participants in the humoral immune response.  When activated they 
secrete Ig, or antibodies, which are essential in neutralizing and destroying pathogens.  
These antibody secreting cells can develop into long-lived memory cells that are 
important in the response against repeat infection.  They can also process and present 
antigen to activate T cells and to receive T cell help.   The role for B cells in immunity is 
diverse, and their dysregulation is a key component in the development of SLE.   
 
Because SLE is characterized by the production of autoantibodies to nuclear components, 
it is clear that hyper-responsive, autoreactive B cells play a central role in the 
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development and pathogenesis of the disease.  Studies show the transfer of pre-B cells 
from lupus-prone (NZB x NZW) F1 mice into mice lacking B cells results in lupus 
symptoms (105).  Further, the development of disease is prevented in lupus-prone 
animals lacking B cells (106, 107).  Patients with SLE have elevated serum levels of 
BLyS which promotes B cell survival and activation (108, 109).   Thus, the abnormal 
activation and survival of B cells results in their targeting for therapy in SLE treatment 
(110).   
 
The process of B cell development and regulation is important in controlling and 
eliminating autoreactive cells.  In lupus-prone mouse models, autoreactive B cells escape 
deletion usually occurs after an encounter with high-affinity antigen (111).   Further, in 
SLE patients, it has been found that early B cell tolerance checkpoints as well as memory 
B cell development are defective (112, 113, 114).  Studies also show that in lupus-prone 
mice, anti-Sm, autoreactive B cells escape the pre-plasma cell checkpoint and become 
antibody secreting cells (ASC) (115).  In mice with Sm-specific B cells that also have 
impaired apoptotic cell clearance, there is a loss of the MZ and B-1 cell populations 
coincident with the ability to circumvent the pre-plamsa cell checkpoint (13, 116).  Mice 
expressing the Yaa mutant gene associated with lupus have a significantly reduced 
transitional 2 and marginal zone (MZ) B cell population (117).  While the authors 
conclude that this is a result of defective development of MZ B cells, it could also be due 
to premature development into plasma cells.   Studies of the NZM Tan mice, who have 
the same susceptibility loci as NZM2410, indicate that these mice do not develop disease 
symptoms, however, the MZ appears to be defective because they do not migrate to the 
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follicle when stimulated and fail to interact with T-independent antigens (118).  In the 
(NZB x NZW) F1 mice the MZ is shown to be expanded and associated with disease 
(119, 120, 121).  These defects in the development and control of autoreactive B cells are 
critical in the development of disease.   
 
Because the SLE B cells are aberrantly activated to produce autoantibodies, it is not 
surprising that B cell signal transduction is abnormal.  Upon activation these cells show 
enhanced tyrosine phosphorylation and intracellular calcium flux compared to normal B 
cells (122).  In lupus-prone animals, resting B cells are shown to be hyper-responsive, 
and express increased costimulatory molecules when stimulated with T-cell associated 
stimuli (123).  As discussed above, FcγRIIb is a negative regulator of BCR signaling.  
Some SLE patients have a defective version of this receptor, while others fail to 
upregulate its expression, contributing to an increase in calcium flux upon activation 
compared to healthy controls and correlates with increased IgG autoantibodies in (NZB x 
NZW) F1 (63, 124).  The expression of inducible costimulator ligand (ICOS-L) is 
downregulated in SLE B cells and is thought to be a result of interaction with ICOS high-
expressing T cells to induce plasma cell differentiation (125).  CD72 can both be a 
positive and negative regulator of BCR signaling.  A study of SLE patients revealed that 
expression of CD72 is reduced and over 95% of patients had mutations in mRNA.  
Roughly half of the mutations were in the tyrosine-based inhibitory motif (ITIM) 
indicating a loss in repressive ability (126).  CD19 is an enhancer of BCR signaling and 
in most SLE patients CD19 expression is lower than normal, however, a population of 
individuals that have high levels of expression on antigen-selected, activated memory B 
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cells (127).  All of these defective components of signaling act to enhance the BCR 
response to stimulation contributing to the hyper-reactivity of these cells. 
 
Mechanisms of B cell Tolerance 
 
Regulation of autoreactive B cells is essential to prevent an immune response to self-
antigens.  Developing autoreactive B cells in the bone marrow and the periphery are 
controlled by tolerance mechanisms including: deletion or receptor editing; and are 
subjected to a checkpoint at the pre-plasma cell stage and another during memory B cell 
development (113, 115).  Low-affinity antigens may not be recognized by the 
autoreactive B cell or may not transduce a strong enough signal through the BCR to 
induce a response, and thus tolerance is maintained by functional ignorance (128).  
During the adaptive immune response B cells can be regulated by the lack of T cell help 
or being positively selected into the B-1 compartment (129, 130, 131).  Exposure of the 
BCR to antigen leads to failure to renew signal transduction, which results in 
desensitization of the BCR signaling complex (132).   
 
Antigen ligation can lead to the destabilization of the BCR signaling complex, which is 
thought to be another regulatory mechanism of B cell tolerance.  The BCR complex 
consists of μ-heavy chain (μm) and Ig-α/β heterodimer.   This signaling complex 
mediates the BCR signal transduction through their immunoreceptor tyrosine-based 
activation motif (ITAM) in their cytosolic tail.  During BCR-mediated signal 
transduction, the Igα/β physically dissociates from the μm indicating a destabilized BCR 
complex.  BCR destabilization was identified as the inability to coprecipitate 
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stoichiometric amounts of Ig-α/β with μm following antigen stimulation (133).  The 
distance of this separation is approximately 200 nm, as quantitated by electron and 
confocal microscopy (134).  Upon antigen ligation to the BCR, autoreactive B cells 
become unresponsive to further stimulation (132).  Destabilization was shown to be 
coincident with receptor desensitization, indicating the destabilization plays a role in 
maintaining autoreactive B cell unresponsiveness.  Further studies showed that if signal-
competent and signal-incompetent receptors were co-aggregated, then signal transduction 
is negatively affected (135).  These studies also showed that if just 15% of the surface 
receptors were signal-incompetent, then the competent receptors were also unable to 
initiate signal transduction (135).  Taken in conjunction with the required constant 
receptor occupancy for B cell anergy (136), this data suggests that a constant receptor 
ligation by antigen would lead to destabilization, aggregation, and attenuation of signal 
transduction that would maintain autoreactive B cells unresponsiveness. 
 
The activation of the innate immune system can cause activation of autoreactive B cells, 
however, there are mechanisms to prevent breaking tolerance each time it encounters 
infection.  B cells that have constant receptor occupancy with antigen will remain angeric 
(136).  Hen egg lysozyme (HEL)-specific B cells that have chronically ligated BCR have 
constitutive ERK activation, which represses Ig secretion induced by CpG, TLR9 
stimulation.  DCs or MΦs are able to repress Sm-specific, low-affinity B cell Ig secretion 
in response to TLR4 stimulation by LPS by secreting soluble mediators, IL-6 and CD40L 
respectively that act on the B cell to attenuate the autoantibody response (103, 104). This 
mechanism of tolerance is not limited to Sm-specific B cells, because HEL-specific B 
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cells from soluble HEL expressing mice and p-azophenylarsonate-specific B cells, that 
are cross reactive with ssDNA, are also regulated by DCs and MΦs during activation of 
the innate immune response (103).  If DC/MΦs are removed from the culture then, the B 
cells are able to secrete in response to LPS indicating that this tolerance is reversible.  
These mechanisms are essential to prevent activating autoreactive cells during innate 
immune stimulation   
 
B cell Tolerance to Sm Murine Models 2-12H and 2-12H/Vκ8 
The response to Sm has been characterized in both humans and the MRL/lpr mouse 
model of SLE (3, 52).  In order to study the regulation of B cells specific for the antigen, 
transgenic mice were developed.  The transgene in these mice is a BCR heavy chain that 
was derived from a hybridoma from MRL/lpr (137).  The 2-12H mouse has a fixed 
heavy-chain that can pair with variable light chains to create a varied, autoreactive B cell 
repertoire (137).  Approximately 30% of the B cells are specific for Sm at varying 
affinity, while the remaining B cells may bind to ssDNA, dsDNA, or have an unknown 
specificity (129, 138, 139).  Despite the large number of B cells specific for nuclear self-
antigen, these mice do not develop autoimmune disease (137).  It is thought these B cells 
are regulated by a variety of tolerance mechanisms including ignorance, anergy, 
developmental arrest and the formation of early pre-plasma cells (115).  In order to 
pinpoint the role of affinity in this Sm-specific response, an Ig-transgenic mouse of 2-
12H is crossed with a mouse expressing Vk8 light chain to generate B cells with low-
affinity for Sm (140).  These mice have low levels of serum transgenic-antibodies, 
indicating that the B cells are not spontaneously activated in vivo (140).  Because these 
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mice do not develop autoimmunity it makes them ideal for studying tolerance 
mechanisms that regulate low-affinity, autoreactive B cells.    
 
Dendritic cells and Macrophages and SLE 
DCs and MΦs have similar roles in the immune response.  They are responsible for 
obtaining antigen and presenting it to activate T cells.   The immunoregulatory effects of 
DC/MΦs are important in the balance between activation of the innate immune system 
and maintaining tolerance to autoantigens.  DCs regulate self-reactive T cells in the 
periphery by inducing their proliferation and apoptosis (141).  MΦs have also been 
shown to repress T cells during infection (142).  MΦ ingestion of necrotic cells causes 
enhanced antigen-presentation (143).  Further, engulfment of necrotic cells results in DC 
maturation and will induce CD4+ and CD8+ T cell responses (144).  DCs that 
phagocytose apoptotic cells, will not be able to efficiently present antigen to T cells; 
however, if they are matured by another stimulus then they are able to cross-present to 
CD8+ T cells (144).  This inability to present stimulatory antigen can lead to induction of 
peripheral tolerance in T cells during steady state conditions (145).  Tolerogenic DCs 
appear to be mature by the expression of cell surface markers, however, they lack of 
production of IL-12 and the ability to produce IL-10 (146). These cells act to drive the 
development of T regulatory cells (147).   Therefore, DC/MΦs not only stimulate the T 
cell response but also have the ability to regulate it as well. 
 
Several studies have demonstrated dysregulation of DCs in both lupus patients and lupus-
prone murine models.  Interestingly, DCs accumulate in older, diseased lupus-prone mice 
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(148, 149).  However, it has been shown that these cells can be defective.  In NZM2410 
mice, CD40 expression on the surface of splenic DCs is increased abnormally prior to 
disease development and it is thought to be a result from stimulation in vivo because 
upregulation does not occur on bone marrow-derived DCs (149).  This may indicate that 
the DCs are being stimulated to mature and survive which could explain the 
accumulation of DCs in diseased animals (150). CD40 can rescue B cells stimulated with 
high-affinity antigen from cell death which may override the tolerance mechanism of 
inducing the death of autoreactive B cells (151).  Another study demonstrated that 
myeloid DCs from SLE patients have increased costimulatory markers, MHC class II, 
and proinflammatory cytokine IL-8; and these DCs caused proliferation and activation of 
T cells (152).  Further, mature DCs would not be able to respond to new stimulation by 
pathogens and therefore contribute to prolonged infection.  The upregulation of the 
costimulatory molecule CD80 is deficient in some patients and NZM2410 and (NZB x 
NZW) F1 (149, 153, 154).  CD80 is able to activate regulatory T cells, and if these cells 
cannot be stimulated by DCs then autoreactive B cells may become activated.  The 
dysregulation of DCs’ ability to maintain a balance between activation of the immune 
system and induce tolerance to self-antigen contributes to the development of SLE.  
   
MΦs are also a key participant in SLE.  In particular, MΦs and T cells accumulate in the 
glomeruli, contributing to glomerulonephritis (155).  Studies of MΦs in lupus-prone mice 
have shown that they have certain defects as well.  Interestingly, their morphology and 
cytoskeleton appears to be quite different from normal mice.  The amount of lupus-prone 
MΦs that adhere in vitro is greatly increased compared to non-autoimmune mice and the 
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reduced activity of the cytoskeleton regulator, Rho, results in a larger cell size (156, 157).  
Extensive studies in murine lupus models show that their MΦs are defective in their 
production of IL-1α, IL-1β, IL-12, and IL-6 in response to stimulation which is intrinsic 
to the MΦs as demonstrated by bone marrow chimeras (158).  Both the defect in IL-1 
production and the differences in morphology are coincident with the presence of lipids 
from fetal bovine serum or apoptotic cells (156, 159).  Given their role in regulation of 
the immune system, defects in MΦ regulation are important in the pathogenesis of SLE.  
 
The clearance of apoptotic cells is essential to maintain tolerance to self-antigen.  
Apoptotic cells display nuclear self-antigen on their surface (11, 13, 14).  Therefore, 
these cells can provide a source of self-antigen to autoreactive BCRs and to TLRs that 
may aberrantly activate the immune system.  Apoptotic cells form IC with soluble 
antibody, resulting in inflammation.  (NZB X NZW) F1 mice have DC/MΦs that are 
defective in their uptake of and destruction of DNA leading to an increase in the 
formation and accumulation of anti-DNA IC (160).  The increased apoptotic load in SLE 
has been shown to be a result of defective uptake by MΦs on the Faslpr background (116, 
161, 162).  DC/MΦs that engulf apoptotic cells present antigen through MHC molecules 
to T cells without upregulating costimulatory molecules to maintain tolerance (145).  
Data indicate MΦs that phagocytose apoptotic cells produce anti-inflammatory response 
upon LPS stimulation (163, 164).  In contrast, DCs stimulated with LPS after engulfing 
apoptotic cells secrete the proinflammatory cytokine TNF-α (144).  During infection in 
patients with SLE where polyclonal activation and exposure to apoptotic cells may occur 
congruently, presentation of apoptotic antigens may become immunostimulatory.  
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Understanding DC/MΦ-mediated tolerance is essential to elucidating how their 
dysregulation contributes to the development of autoimmunity.  
 
DC: B cell interaction 
DCs can display antigen on their surface by mechanisms other than MHC peptide 
presentation.  When pulsed with exogenous antigens, such as HEL or human serum 
albumin, they internalize, maintain intracellular pools of antigen, and recycle them, 
intact, back to their surface (165).  In another mechanism, FcγRIIb has been shown to 
mediate the uptake and recycling of IC with OVA to the DC surface (65).  In fact, it was 
demonstrated that this presentation of intact exogenously loaded antigen to results in DCs 
interacting with antigen-specific B cells (65, 165, 166, 167).  Both in vitro and in vivo 
experiments showed that B cells can recognize and acquire surface-antigen on DCs.   
This interaction results in T cell independent signal transduction and T cell dependent 
class switching to produce Ig (65, 165, 166, 167, 168).   Therefore, DCs display 
exogenous native antigen in a form that B cells may encounter through their BCR.  The 
contact between DCs and B cells through intact antigen interacting with the BCR is of 
interest in the study of B cell tolerance and activation mechanisms. 
 
Model for DC/MΦ-Mediated B cell Tolerance 
Our previous studies show that during polyclonal activation, antigen-experienced, 
autoreactive B cells are regulated by myeloid (my)DCs and MΦs.  LPS-stimulated 
DC/MΦs secrete soluble mediators that prevent the B cells from secreting Ig, 
specifically, IL-6 and TNF-α while MΦs produce CD40 ligand (CD40L) ((103, 104) 
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Gilbert MR and Vilen BJ manuscript in preparation).  This mechanism regulates several 
different BCR transgenic mouse models that are specific for self-antigen, including:  low-
affinity Sm (2-12H/Vκ8), p-azophenylarsonate (Ars), and HEL (103).  Only chronically 
antigen experienced mice are sensitve to the DC/MΦ-mediated regulation, therefore, we 
believe that the constitutive ligation of the BCR with antigen modulates the response to 
the soluble mediators, and this mechanism is dependent on ERK (Rutan JA manuscript in 
preparation).  Autoreactive, follicular (FO) B cells are repressed by both DCs and MΦs 
while MZ B cells are only susceptible to inhibition by MΦs (104).  The MΦ secreted 
CD40L inhibits autoreactive MZ B cell Ig by preventing their development into plasma 
cells by downregulating the transcription factors Blimp-1 and XBP-1 required for 
differentiation into antibody secreting cells  (104).  Understanding this DC/MΦ-mediated 
mechanism to regulate LPS-stimulated autoreactive cells is important in further 
elucidating how self-tolerance is maintained to prevent autoimmune disease. 
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Abstract 
 
Autoimmunity results from a breakdown in tolerance mechanisms that regulate 
autoreactive lymphocytes.  We recently showed that during innate immune responses, 
secretion of IL-6 by dendritic cells (DCs) maintained autoreactive B cells in an 
unresponsive state.  Here we describe that TLR4-activated DCs from lupus-prone mice 
are defective in repressing autoantibody secretion, coincident with diminished IL-6 
secretion.  Reduced secretion of IL-6 by MRL/lpr DCs reflected diminished synthesis 
and failure to sustain IL-6 mRNA production.  This occurred coincident with lack of NF-
κB and AP-1 DNA binding and failure to sustain IκBα phosphorylation.  Analysis of 
individual mice showed that some animals partially repressed Ig secretion despite 
reduced levels of IL-6.  This suggests that in addition to IL-6, DCs secrete other soluble 
factor(s) that regulate autoreactive B cells.  Collectively, the data show that MRL/lpr 
mice are defective in DC/IL-6-mediated tolerance, but that some individuals maintain the 
ability to repress autoantibody secretion by an alternative mechanism.  
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Introduction 
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease characterized 
by the production of autoantibodies to nuclear components.  Alternating periods of flares 
and remissions are associated with an increased burden of apoptotic cells, the formation 
of immune complexes, and inflammation (169).  The etiology of SLE remains unknown; 
however, multiple immunoregulatory defects have been identified in lupus-prone mice 
(69, 96, 159, 170, 171, 172, 173, 174, 175, 176, 177, 178), including complement 
deficiencies, TCR signal transduction anomalies, and dysfunctional cytokine secretion by 
macrophages (MΦs).  These defects contribute to the onset and/or pathogenesis of SLE, 
while a breakdown in tolerance leads to the formation of autoantibodies and immune 
complexes that may play a role in vasculitis, glomerulonephritis, and cerebritis (179). 
 
Studies in immunoglobulin (Ig) transgenic (Tg) mouse models have defined anergy as a 
state of unresponsiveness that regulate autoreactive B cells in the periphery (128, 140, 
180, 181, 182).  Anergic B cells fail to secrete antibody in response to LPS or antigen 
immunization due to receptor unresponsiveness (140, 181, 183).  Some anergic B cells 
exhibit reduced surface IgM levels (184, 185), decreased lifespan (183, 186), and 
exclusion from the lymphoid follicle (186, 187).  In the case of B cells specific for the 
lupus-associated antigen, Smith (Sm), a partially anergic phenotype is evident.  Sm-
specific B cells from 2-12H/Vκ8 Ig Tg mice are unable to secrete Ig in response to LPS, 
yet maintain surface IgM levels, exhibit a normal lifespan, and remain competent to enter 
the B cell follicle (140).  Recently, we described that Sm-specific B cells purified from 
myeloid dendritic cells (myDCs) and MΦs regain the ability to secrete Ig in response to 
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LPS (103).  The data show that secretion of IL-6 by DC/MΦs represses LPS-induced Ig 
secretion by autoreactive B cells without repressing acutely stimulated naïve B cells.  
This mechanism of tolerance is not limited to Sm-specific B cells as chronically antigen-
experienced HEL- and Ars/A1-specific B cells are similarly affected (103).  These 
findings identify a unique mechanism of B cell tolerance wherein DCs and MΦs play a 
central role in regulating autoimmunity during innate immune responses.  
 
MyDCs and plasmacytoid DCs have been described as positive regulators of immunity 
promoting growth and differentiation of some B cells through the secretion of IL-12, IL-
6, BLyS, and APRIL (101, 188, 189).  Specifically, IL-6 was found to promote plasma 
cell survival (190, 191).  Although this seems paradoxical, the data indicate that IL-6 
differentially regulates naïve and chronically antigen-experienced B cells (103).  Studies 
identifying IL-6 as a positive regulator focused on B cells from non-Tg mice where the 
proportion of autoreactive cells is low.  In contrast, the studies showing that IL-6 
represses autoantibody production used self-reactive Ig Tg models where the B cells were 
constantly exposed to self-antigen (103).  Thus, IL-6 acts as a positive or negative 
regulator of B cells depending on the history of BCR ligation.  We propose that chronic 
BCR ligation by self-antigen reprograms IL-6R-mediated outcomes allowing naïve B 
cells to produce Ig in response to polyclonal stimulation while simultaneously repressing 
autoreactive B cells from producing autoantibody.  These findings identify a novel B cell 
tolerance mechanism, and suggest that overcoming tolerance in SLE might be associated 
with defects in the repression of autoreactive B cells by myDCs and/or MΦs.  
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In this report, we show that LPS-activated DCs from MRL/lpr mice inefficiently repress 
Sm-specific Ig secretion, coincident with diminished IL-6 secretion.  Mechanistically, 
diminished secretion of IL-6 resulted from decreased synthesis of IL-6 mRNA coincident 
with decreased IκBα phosphorylation and reduced DNA binding by NF-κB and AP-1.  
These data identify signal transduction defects in DCs that occur coincident with 
diminished IL-6 secretion and failure to repress Ig secretion by autoreactive B cells.  
Further analysis of DC-mediated tolerance mechanisms revealed that DC conditioned 
medium (CM) from some MRL/lpr mice repressed Ig secretion despite low levels of IL-
6.  This suggested that additional soluble factors are involved in repressing autoantibody 
secretion.  These findings implicate DC defects in the breakdown of tolerance in lupus-
prone mice and suggest that defects in multiple factors may be required for the complete 
breakdown of tolerance associated with autoimmunity.  
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Materials and Methods 
Mice 
 
2-12H/Vκ8/Cκ-/- immunoglobulin transgenic mice were previously described (103, 140).  
MRL/MpJ-Faslpr/J (MRL/lpr) and C57BL/6J (B6) mice were purchased from The 
Jackson Laboratory, and NZM2410 mice from Taconic.  NZBxNZWF1 mice were 
obtained from Trine Jorgensen (University of Colorado), MRL/MpJ (MRL) and B6.Faslpr 
(B6.lpr) from Stephen Clarke (University of North Carolina).  2-12H/Vκ8/Cκ-/- mice 
were used at 9-17 weeks of age.  All other mice were used at 6-10 weeks old.  All studies 
were approved by the Institutional Animal Care and Use Committee. 
 
Reagents and Antibodies 
 
7-AAD, rIL-6, and antibodies to CD11c, CD11b, B220, and IL-6 were purchased from 
BD Biosciences, GR1 and TLR4 from eBiosciences, phospho-IκBα from Cell Signaling, 
IκBα and β-tubulin from Santa Cruz, and IgG HRP from Promega.  Streptavidin-AP was 
purchased from Southern Biotech, anti-actin, TEPC 183, and Escherichia coli 055:B5 
LPS from Sigma Aldrich, 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) from 
Calbiochem, E.  coli 0111:B4 LPS from List Biological Laboratories, mouse GM-CSF 
and IL-4 from PeproTech, poly (I:C) and R848 from InvivoGen, and CpG 
oligodeoxynucleotides (ODN) and non-CpG ODN from Coley Pharmaceutical Group.  
JA12.5, 54.1, 187.1, HB100, and CRL 1969 were purified from hybridoma culture 
supernatant. 
 
Cell Purification 
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B cells were purified from 2-12H/Vκ8/Cκ-/- spleens by negative selection (StemCell 
Technologies) (103).  Biotinylated CD3 antibody was added to the antibody cocktail to 
increase the efficiency of T cell depletion.  B cells were 86-93% pure with <3% T cells 
and <7% DCs/MΦs.  Splenic CD11c+ cells (~70% pure) were purified by positive 
selection (Miltenyi Biotec) and found to contain 20% lymphocytes and 10% MΦs.   
 
Bone marrow-derived DC (BMDC) Cultures 
 
Bone marrow-derived DCs were generated as previously described (103).  BMDCs were 
>95% CD11c+ (CRL 1969 hybridoma).  Conditioned medium (CM) was made from 
1x104 BMDCs (0.2 ml) cultured for an additional 4 days with or without Sigma LPS (30 
μg/ml).  5x105 BMDCs (0.2 ml) were cultured for an additional 4 days with or without 
poly (I:C) (50 μg/ml), R848 (10 μg/ml), CpG ODN (1 μg/ml), or non-CpG ODN (1 
μg/ml).  In experiments where RNA was isolated or nuclear extracts were prepared, 
BMDCs were stimulated with E. coli 0111:B4 LPS (List Biological Laboratories) that 
was re-purified (192) and confirmed to be unable to induce IL-6 secretion by TLR4-/- 
DCs.  
 
B cell Cultures 
 
Splenocytes containing 1x105 B cells, or the equivalent number of purified B cells, were 
cultured with Sigma LPS (30 μg/ml) for 4 days.  In the mixed B cell experiments, 
purified B6 (5x104; IgMb) and 2-12H/Vκ8 (5x104; IgMa) B cells were cocultured with 
LPS for 4 days as above.  BMDCs, CD11c+ splenocytes, or BMDC CM (25% of final 
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volume) were added to B cell cultures on day 0.  The IL-6 in DC CM was neutralized 
with either anti-IL-6 antibody or a control rat IgG1 antibody (54.1).  
 
ELISA 
 
IgMa/κ (encoded by 2-12H/Vκ8/Cκ-/-) was captured with anti-κ (187.1), detected with 
biotinylated anti-IgMa (HB100) and Streptavidin-AP as previously described (140).  
Purified mouse IgMa/κ (TEPC 183) served as the standard control.  IgMa/κ levels were 
plotted as “percent of control” defined by the level of Ig secretion in LPS-stimulated 
cultures of purified 2-12H/Vκ8/Cκ-/- B cells (100%).  IL-6 was quantitated by capturing 
with anti-IL-6 (clone MP5-20F3) and detecting with biotinylated anti-IL-6 (clone MP5-
32C11) and Streptavidin-AP.  Recombinant IL-6 served as the standard control.  
 
Real time (RT)-PCR  
RNA was prepared from BMDCs treated with re-purified LPS (15 μg/ml) by 
solubilization in Trizol (Invitrogen) and treatment with Turbo DNase (Ambion).  Reverse 
transcription with oligo(dT) primers was performed with Superscript II (Invitrogen).  The 
amount of IL-6 message was determined using the TaqMan Assay-On-Demand primer-
probe sets (Applied Biosystems) and the ABI 7000 sequence detection system.  IL-6 
mRNA transcript levels were normalized to the amount of 18S ribosomal RNA 
transcription according to the following equation: %18S = 2^ [-(IL-6 – 18S units)].  To 
measure IL-6 mRNA stability, BMDCs were stimulated with re-purified LPS (15μg/ml) 
for 6 hrs and then treated with 50 μM DRB for 15, 30, and 60 min to block transcription.  
mRNA was quantitated by RT-PCR as described above. 
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 Electrophoretic Mobility Shift Assay (EMSA)  
BMDCs were stimulated with re-purified LPS (15 μg/ml) and gel shift assays were 
performed as previously described (193).  
 
Statistical Analysis 
 
Exact Wilcoxon rank sum test was used for most unpaired two-sample comparisons.  
When total sample size was small (<8), t test was used instead.  For test differences 
between paired observations, exact Wilcoxon signed rank test was used.  p values < 0.05 
were considered significant and denoted by *.  
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Results  
The frequencies of splenic myDCs and MΦs are not diminished in MRL/lpr mice. 
Maintaining B cell tolerance during activation of the innate immune system is crucial in 
preventing autoimmunity.  We have previously shown that stimulation through TLR4 
activates myDCs and MΦs to secrete soluble factors thereby repressing Ig secretion by 
chronically antigen-experienced (autoreactive) B cells (103).  To determine if the 
breakdown of tolerance in lupus-prone mice was associated with the lack of a repressive 
cell type, we compared the frequency of splenic MΦ and DC subsets in MRL/lpr and B6 
mice.  As shown in Figure 2.1 and Table I, the frequencies of myDCs 
(CD11chi/CD11bint/hi) and plasmacytoid DCs (pDCs, CD11clo/CD11b-/B220+/GR1+) were 
not significantly different.  The lymphoid DCs (lyDCs, CD11clo/CD11b-/B220-/GR1-) 
were significantly decreased in MRL/lpr, however this population is not involved in 
DC/MΦ-mediated tolerance (103).  The CD11c-/CD11bhi and CD11c-/CD11blo 
populations were increased in MRL/lpr mice, raising the possibility that these 
populations might secrete an activator that enhances Ig secretion.  However, when 
isolated by cell sorting, these populations did not augment LPS-induced Ig secretion or 
affect the ability of B6 DCs to regulate Ig secretion by Sm-specific B cells (data not 
shown), suggesting that neither population promotes the loss of B cell tolerance.  Thus, 
neither diminished frequency of myDCs and MΦs nor secretion of an activator accounts 
for the loss of tolerance in MRL/lpr mice. 
 
DCs from MRL/lpr mice fail to efficiently repress Sm-specific B cells.   
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LPS-activated DCs from B6 mice regulate chronically antigen-experienced B cells (103).  
To assess if DCs from MRL/lpr mice were capable of repressing Ig secretion, we 
cocultured Sm-specific B cells with bone marrow-derived DCs (BMDCs) from B6 or 
MRL/lpr mice (Figure 2.2A).  Compared to B6 DCs, MRL/lpr DCs were less efficient at 
repressing Sm-specific B cells when cultured at B cell: DC ratios of 10:1, 20:1, and 100:1 
(p = 0.016, 0.004, and 0.015 respectively).  These differences were not due to 
contaminating cells, because BMDCs from B6 and MRL/lpr mice contained >95% 
myDCs, and sorted B cells compared to negatively selected B cells from 2-12H/Vκ8 
mice cultured with DCs from MRL/lpr mice exhibited similar results (data not shown).  
To determine if splenic DCs were also defective in repressing autoreactive B cells, 
splenic CD11c+ cells were isolated from B6 and MRL/lpr mice, and cocultured with B 
cells from 2-12H/Vκ8 mice (B cell: DC ratio 10:1).  As shown in Figure 2.2B, ex vivo B6 
DCs repressed significantly better than DCs purified from MRL/lpr mice (p = 0.015), 
indicating that the defect was not specific to BMDCs.  Collectively, the data indicate that 
myDCs from MRL/lpr mice are present at a normal frequency, but they are defective in 
repressing Ig secretion by autoreactive B cells.   
 
DCs from MRL/lpr mice are defective in IL-6 secretion 
 
We previously showed that IL-6 secreted by DCs repressed autoreactive B cells (103).  
To determine if diminished IL-6 was associated with the inability of MRL/lpr DCs to 
repress Sm-specific Ig secretion, we measured IL-6 secretion.  LPS-activated BMDCs 
(Figure 2.3A) and splenic CD11c+ cells (Figure 2.3B) from MRL/lpr mice secreted 
significantly less IL-6 compared to B6 controls (p < 0.001 and p = 0.003 respectively).  
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To assess if this defect was unique to MRL/lpr mice, we quantitated LPS-induced IL-6 
secretion from BMDCs from several other lupus-prone models.  As shown in Figure 
2.3A, BMDCs from MRL, NZM2410, and NZBxNZWF1 were defective in secreting IL-6 
when compared to B6 (p < 0.0001, p < 0.0001, and p = 0.002 respectively).  Interestingly, 
B6.lpr mice were not defective in secreting IL-6 (p = 0.932), suggesting that the inability 
to secrete IL-6 is associated with the MRL background.  Defective IL-6 production was 
not secondary to IL-10 inhibiting TLR signaling, as MRL/lpr DCs secreted decreased 
levels of IL-10 and neutralizing IL-10 did not restore IL-6 levels (data not shown).  To 
determine whether defective IL-6 secretion was limited to stimulation through TLR4, we 
measured IL-6 secretion from MRL/lpr-derived DCs in response to other TLR ligands.  
As shown in Figures 2.3C-E, IL-6 secretion was increased when MRL/lpr BMDCs were 
stimulated through TLR3 (poly (I:C), p = 0.006); however, secretion was defective when 
stimulated through TLR7 (R848, p = 0.028) and TLR9 (CpG ODN, p = 0.016).  This 
indicates that not all TLRs are affected by this defect, and that mutation within the IL-6 
structural gene is unlikely to explain the reduced levels of IL-6.  Collectively, the data 
indicate that DCs from multiple strains of autoimmune mice exhibit defects in cytokine 
secretion induced through some TLRs. 
  
Diminished IL-6 secretion is not due to decreased TLR4 expression or survival. 
Expression of TLRs ensures that DCs are activated during innate immune responses.  It 
was possible that the decreased secretion of IL-6 from MRL/lpr DCs reflected a reduced 
expression of surface TLR4.  As shown in Figure 2.4A, the expression of TLR4 on 
myDCs from B6 (MFI 58.9 + 12.6) and MRL/lpr (MFI 68.1 + 10.9) mice was not 
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significantly different.  Likewise, BMDCs from B6 and MRL/lpr mice did not differ in 
TLR4 expression (data not shown), nor did they differ in viability as determined by 7-
AAD staining at day 4 (Figure 2.4B).  Thus, diminished surface expression of TLR4 or 
decreased survival do not account for the decreased IL-6 secretion by LPS-activated DCs 
from MRL/lpr mice.   
 
Defective IL-6 secretion is associated with failure to sustain IL-6 transcription. 
Transcriptional regulation of IL-6 depends on several signal transduction pathways that 
activate multiple transcriptional regulators including NF-κB and AP-1.  To determine if 
the diminished secretion of IL-6 by MRL/lpr DCs was due to defective transcriptional 
regulation, we LPS-stimulated BMDCs from B6 and MRL/lpr mice and quantitated IL-6 
mRNA levels by real time (RT)-PCR.  The basal level of IL-6 mRNA in the MRL/lpr 
mice was slightly lower than in B6 mice (Figure 2.5A).  Upon stimulation with LPS, IL-6 
mRNA levels in B6 and MRL/lpr DCs were dramatically increased; however, the 
magnitude of the response by MRL/lpr BMDCs was 7-fold lower.  Further, the sustained 
levels of IL-6 mRNA production were higher in B6 compared to MRL/lpr mice (24 hr 
and 96 hr timepoints).  To determine if decreased mRNA stability contributed to the 
decreased production of IL-6 message, BMDCs were LPS-stimulated for 6 hours 
followed by pharmacological attenuation of transcription.  The levels of IL-6 mRNA in 
BMDCs from B6 and MRL/lpr mice were quantitated by RT-PCR.  As shown in Figure 
2.5B, the rates of mRNA degradation in the MRL/lpr DCs did not change over time; 
however, the IL-6 mRNA levels in B6 DCs were reduced by 3-fold within 15 minutes of 
attenuating new transcription.  This indicates that IL-6 message is inherently unstable and 
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that sustained production of IL-6 mRNA requires continual synthesis.  Further, given that 
degradation was not observed in DCs from MRL/lpr mice, the data indicate that 
increased degradation does not contribute to the diminished IL-6 mRNA levels.  This 
suggests that MRL/lpr DCs harbor a defect at or upstream of transcriptional initiation that 
reduces the level of IL-6 mRNA and protein.   
 
To assess if decreased IL-6 mRNA levels were associated with defects in NF-κB or AP-1 
activation, we compared the DNA binding activity in nuclear extracts prepared from B6 
and MRL/lpr DCs.  The DNA binding activity of NF-κB from LPS-stimulated B6 DCs 
occurred within 10 minutes, with robust binding at 6 hours.  In contrast, the DNA binding 
activity of NF-κB from MRL/lpr DCs was diminished at these same timepoints (Figure 
2.6A).  This was not a reflection of unequal protein loading, as the levels of an unrelated 
nuclear protein (PCNA) were comparable.  The specificity of NF-κB for the DNA probe 
was confirmed by diminished complex formation in the presence of unlabelled probe 
(competitor DNA), and failure of a mutant competitor DNA (mutant DNA) to reduce 
complex formation (Figure 2.6B).  To identify the NF-κB subunits involved in DNA 
binding, we supershifted the DNA/protein complex with subunit-specific antibodies.  As 
shown in Figure 2.6C, p65 and c-Rel, but not p50, were identified as components of the 
NF-κB complex formed in B6 DCs following 6 hour LPS stimulation.  p65 and c-Rel 
anti-sera were specific for these components as pre-immune serum failed to supershift a 
protein/DNA complex (data not shown).  Similar to NF-κB, DNA binding by AP-1 was 
also markedly diminished in DCs from MRL/lpr compared to B6 mice (Figure 2.6D).  
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Thus, LPS-stimulated MRL/lpr DCs fail to activate key transcriptional regulators 
required for IL-6 gene transcription.   
 
Nuclear translocation of NF-κB is dependent on phosphorylation and degradation of IκB 
(194).  To assess if the lack of NF-κB DNA binding was associated with defects in IκB 
phosphorylation/degradation, we immunoblotted whole cell lysates from LPS-stimulated 
B6 and MRL/lpr BMDCs.  B6 DCs showed induced phosphorylation of IκBα at 5 
minutes that was sustained through 6 hours (Figure 2.7A, left panel).  In contrast, 
MRL/lpr DCs induced IκBα phosphorylation at 5 minutes with maximal phosphorylation 
at 15 minutes.  Phosphorylation was not evident at 45 minutes or 6 hours (Figure 2.7A, 
right panel).  Similarly, IκBα degradation was delayed following LPS stimulation of 
MRL/lpr DCs, indicating that defects in TLR4-induced signal transduction correlate with 
lack of IL-6 mRNA production and protein secretion.  To assess if other TLR pathways 
in MRL/lpr DCs were similarly affected, we assessed IκBα phosphorylation in response 
to TLR3 ligation.  We showed in Figure 2.3 that despite defects in TLR4-, TLR7- and 
TLR9-induced IL-6 production, TLR3-induced IL-6 production was enhanced.  This 
revealed that the defect in IL-6 production by MRL/lpr DCs did not affect all TLRs.  To 
correlate TLR-induced protein secretion with TLR-mediated signal transduction, we 
assessed IκBα phosphorylation in response to poly (I:C).  As shown in Figure 2.7B, poly 
(I:C)-induced IκBα phosphorylation was comparable between DCs derived from B6 and 
MRL/lpr mice.  Collectively, the data suggest failure to sustain IκBα phosphorylation 
reduces NF-κB activation, diminishes IL-6 transcription, and ultimately decreases IL-6 
protein synthesis by MRL/lpr DCs.  This supports the idea that continuous TLR4 signal 
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transduction is required to maintain IL-6 secretion and suggest this is defective in DCs 
from lupus-prone mice (195).  
 
Autoantibody secretion is repressed by IL-6 and other soluble factors. 
 
We have previously shown that IL-6 repressed 75% of Ig secretion by Sm-specific B 
cells.  Here, we show that DCs from lupus-prone MRL/lpr mice exhibit markedly 
decreased IL-6 levels coincident with their inability to regulate Ig secretion.  To 
determine the importance of decreased IL-6 in the breakdown of tolerance, we assessed 
the ability of conditioned medium (CM) from B6 and MRL/lpr DCs to repress Ig 
secretion.  CM allowed us to distinguish the effects of soluble mediators from the effects 
of cell contact.  As shown in Figure 2.8A, DC CM from most B6 mice repressed 70-90% 
of Ig secretion.  In contrast, the ability of DC CM from individual MRL/lpr mice to 
repress Ig secretion was extremely variable (10-90% repression, p= 0.004).  Given the 
central role for IL-6 in repressing autoantibody secretion (103), we reasoned that if IL-6 
were the sole repressive factor, there would be a direct correlation between IL-6 in DC 
CM and Ig secretion.  However, this broad range of repression only partially correlated 
with IL-6 levels (data not shown).  Despite the fact that all MRL/lpr mice exhibited low 
levels of IL-6, four individuals still repressed 80-90% of Ig secretion (Figure 2.8A).  To 
assess if the low levels of IL-6 secreted by MRL/lpr mice contributed to Ig repression, we 
neutralized any remaining IL-6 in the DC CM of mice retaining repressive function, then 
assessed the ability of the CM to regulate Ig secretion.  As shown in Figure 2.8B, 
neutralization partially restored Ig secretion (p = 0.031), confirming that that the low 
levels of IL-6 regulated Ig secretion.  Interestingly, secretion comparable to controls 
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(100%) was never attained, suggesting that in addition to IL-6, other DC-derived soluble 
mediators regulate Ig secretion.  It was possible that the variability in repression by 
MRL/lpr DC CM was due to the secretion of an activating factor by the MRL/lpr DCs.  
We addressed this in two ways.  First, we added recombinant IL-6 (rIL-6) to the MRL/lpr 
DC CM, and then assessed Ig secretion by Sm-specific B cells.  When added to the CM 
from three individual mice, rIL-6 repressed Ig secretion indicating that if activating 
factors were present, they did not override the repressive effect of IL-6 (data not shown).  
In a second experiment, we assessed if MRL/lpr DCs secreted an activator by 
determining if MRL/lpr DC CM activated naïve B6 B cells.  We previously showed that 
DC CM did not repress naïve B cells (103); thus, the presence of an activator may be 
more evident when Ig secretion is not simultaneously being repressed by the low levels of 
IL-6 in the MRL/lpr DC CM.  The data indicate that MRL/lpr DC CM did not increase Ig 
secretion of naïve B6 B cells, indicating that the dysregulated production of an activator 
is unlikely (data not shown).  
 
Collectively, the data indicate that during innate immune responses, IL-6 and another 
repressive factor(s) regulates B cells chronically exposed to antigen.  Further, this 
mechanism appears defective in lupus-prone mice coincident with diminished secretion 
of IL-6.  However, it remained unclear if soluble factors secreted by LPS-activated DCs 
repressed autoreactive B cells when present in mixed populations with naïve cells.  To 
assess this, we cocultured naïve (B6) and autoreactive (2-12H/Vκ8) B cells with DC CM 
prepared from B6 and MRL/lpr DCs.  As shown in Figure 2.8C, DC CM prepared from 
B6 cells, but not MRL/lpr cells, repressed Ig secretion in the mixed B cell cultures (p = 
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0.009) (Figure 2.8C).  The data suggest that DC-mediated repression regulates mixed 
populations of autoreactive and naïve B cells.
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Discussion 
The defects leading to the breakdown in B cell tolerance remain a central focus in 
understanding SLE.  Previous studies showed that during innate immunity Sm-specific B 
cells were regulated by myDCs and MΦs through the secretion of soluble mediators 
(103).  We propose a model where polyclonal activators stimulate myDCs and MΦs to 
secrete IL-6, which selectively represses autoreactive B cells, while naïve B cells mount a 
polyclonal antibody response to bacterial and viral antigens.  In this report, we show that 
DCs from lupus-prone mice are less efficient at repressing autoreactive B cells coincident 
with a defect in secreting IL-6.  This DC defect was not due to decreased survival or 
TLR4 expression, lack of a regulatory DC subpopulation, or the secretion of factors that 
enhance Ig secretion.  Instead, the reduced IL-6 secretion resulted from the inability of 
MRL/lpr DCs to induce or maintain IL-6 transcription in response to LPS.  Analysis of 
upstream signaling effectors showed that, although LPS induced IκBα phosphorylation, 
it was not sustained.  Further, DNA binding by NF-κB and AP-1 were markedly 
decreased.  These findings indicate that MRL/lpr DCs exhibit a TLR4 signal transduction 
defect at, or upstream of, IκB kinase (IKK)/IκB/NF-κB activation that results in 
diminished IL-6 mRNA production and protein secretion.  
 
Previous data showed that rIL-6 effectively regulated chronically antigen-experienced B 
cells (103).  At several B cell: DC ratios, MRL/lpr DCs were less efficient at repressing 
Ig secretion compared to B6 DCs.  However, despite significant defects in IL-6 secretion, 
they still repressed 53% of anti-Sm secretion at a ratio of 100:1 (Figure 2.2A).  Further, 
DC CM was less efficient at repressing Ig secretion compared to intact DCs indicating 
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that a contact-dependent mechanism might partially regulate Ig secretion.  In support of 
this, we have observed that DCs deficient in TLR4 partially repressed LPS-induced Ig 
secretion; however, repression was lost when the cells were separated in a transwell 
apparatus (Kilmon and Vilen, unpublished observations). 
 
The finding that repression of Ig secretion by DCs is multifaceted fits well with the 
heterogeneity of human disease.  We propose that defects in any regulatory component 
may predispose to autoimmunity, but complete loss of tolerance requires multiple 
defects.  Our data show that the repressive ability of LPS-activated MRL/lpr DCs was 
variable.  Some DCs efficiently repressed Ig secretion, despite diminished IL-6 
production (Figure 2.2, 2.3A/B, 2.8A), while others failed to repress secretion coincident 
with reduced IL-6 levels.  Compared to the contact-dependent mechanism described 
above, this repressive activity was apparent in the CM from some MRL/lpr mice, 
indicating that DCs secrete additional repressive factors that contribute to the regulation 
of Ig secretion.  Thus, despite markedly decreased IL-6 secretion by DCs from all mice 
analyzed, some likely harbor defects in another repressive factor(s) making them more 
susceptible to autoimmunity during innate stimulation.  Although a direct correlation 
between Ig secretion and IL-6 levels in MRL/lpr mice was not evident, we favor the 
interpretation that IL-6 and another repressive factor regulates Ig secretion because IL-6 
deficient DCs repress LPS-induced Ig secretion (unpublished observations) and 
neutralizing IL-6 only partially restored Ig secretion (Figure 2.8B).  This indicates that 
the low levels of IL-6 secreted by MRL/lpr DCs partially represses Ig secretion, but that 
IL-6 is not the sole means of regulating autoimmunity during innate immune responses. 
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 The inability of LPS-stimulated MRL/lpr DCs to produce IL-6 and efficiently repress Ig 
secretion suggests that defects in innate immune responses contribute to autoimmunity.  
Our data show that DCs derived from MRL/lpr mice are unable to sustain IκB 
phosphorylation, thereby reducing NF-κB DNA binding and IL-6 mRNA synthesis.  This 
suggests an intrinsic defect where lack of sustained TLR-mediated signal transduction 
leads to decreased IL-6 protein secretion.  This could reflect a defect in the TLR signaling 
pathway or possibly the selective formation of NF-κB complexes that are less 
transcriptionally active.  Aberrant cytokine production and abnormal NF-κB activity in T 
cells and MΦs from lupus-prone mice and lupus patients have been associated with 
decreased p65, increased p50 homodimers which are more inhibitory to gene 
transcription, reduced binding of p50/c-Rel and p65 NF-κB complexes, and increased 
activity of histone deacetylases (196, 197).  Unfortunately we could not identify the NF-
κB subunits formed by MRL/lpr DCs because DNA binding was not observed at levels 
sufficient for supershifting. 
 
MyD88-dependent, TLR-induced activation of NF-κB and AP-1 is mediated through 
TRAF6 (198).  Thus, the findings that both NF-κB and AP-1 DNA binding activity are 
reduced (Figure 2.6), and that IL-6 secretion and IκBα phosphorylation are defective 
only upon stimulation through MyD88-dependent TLRs (TLR4, 7, and 9, but not TLR3), 
suggest a defect in the MyD88-dependent signaling pathway possibly at or upstream of 
TRAF6.  Alternatively, a defect at the level of the TLR4 receptor may occur.  Yang et al 
showed that persistant TLR4 signals are required for normal DC secretion of IL-6 (195).  
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In the case of dysfunctional MRL/lpr DCs, the TLR4 receptor may become desensitized 
to LPS following an initial stimulus, mimicking LPS removal and causing the decreased 
phospho-IκBα and IL-6 mRNA levels seen at later timepoints (Figures 2.5 and 2.7).   In 
addition, exposure to apoptotic cells may affect the TLR4 response.  Apoptotic cells fail 
to induce inflammatory responses, in part by repressing DC activation (199).  Thus, the 
increased burden of apoptotic cells associated with SLE may dysregulate some of the 
TLRs, rendering them incapable of secreting cytokines that are needed to repress 
autoantibody secretion.  In support of this, others have shown that apoptotic cells cause 
defective IL-6 secretion by macrophages (159), and mice functionally deficient in the 
phagocytosis of apoptotic cells get a lupus-like disease (177).  
 
Increased production of pro-inflammatory cytokines such as IL-6, contribute to the 
inflammatory response and pathogenesis of lupus nephritis (200, 201).  SLE patients (99, 
202, 203, 204) and diseased, lupus-prone mice (205, 206, 207) exhibit elevated serum IL-
6 levels (2-19 pg/ml), yet fail to repress Ig secretion.  Although elevated, this level of 
systemic IL-6 is insufficient to repress autoreactive B cells in vitro (103).  Therefore, we 
propose that colocalization of DCs and B cells is necessary to provide sufficient IL-6 to 
repress Ig secretion.  Our findings showed that DCs derived from MRL/lpr mice secrete 
reduced levels of IL-6, coincident with lack of Ig repression.  We propose that once 
tolerance is overcome, autoantibody secretion and immune complex formation induce 
systemic production of pro-inflammatory mediators, promoting inflammation and 
pathogenesis.  Consistent with this model, CpG-stimulated dendritic cells from SLE 
patients produced lower levels of IL-6 (208), while endothelial cells (209, 210, 211), 
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mesangial cells in the kidney (212, 213), and infiltrating monocytes/macrophages (214) 
secrete elevated levels of IL-6.  This suggests that IL-6 plays a beneficial role when 
released in a local microenvironment between myDCs and autoreactive B cells, yet when 
elevated systemically, it induces inflammation, tissue destruction, and spontaneous Ig 
production by activated B cells (99, 215, 216, 217).  Therapies aimed at neutralizing the 
inflammatory effects of IL-6 may have short-term benefits in treating lupus nephritis, 
however, they are likely to promote loss of tolerance in newly emerging B cells during 
innate immune activation. 
 
Immunoglobulin secretion by B cells is induced by ligation of the TLR and/or BCR.  
BCR-induced Ig secretion is regulated by lack of T cell help and sustained BCR-induced 
calcium signaling and prolonged Erk activation (133, 183, 218, 219).  In contrast, TLR-
induced Ig secretion is regulated by soluble factors secreted from DCs and MΦs (103).  
Although the mechanisms regulating the BCR and TLR are unique, signals derived from 
chronic BCR stimulation impact TLR-induced activation.  For example, the chronic Erk 
activation associated with continuous exposure to self-antigens represses TLR9-induced 
Ig secretion, whereas, acute Erk activation following BCR stimulation of naïve B cells 
promotes TLR9-induced Ig secretion (91, 220).  Similarly, chronic BCR exposure to self-
antigen reprograms IL-6R signal transduction to repress Ig secretion (103).  However, B 
cells that have been acutely stimulated and exposed to IFN-α/β induce Ig secretion in 
response to IL-6 (101).  Our data expand our understanding of IL-6 to include a role in 
repressing Ig secretion by autoreactive B cells.  During autoimmunity, the tolerance 
mechanisms that regulate autoreactive B cells become dysregulated.  For many B cells 
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with autoreactive specificities, it remains unclear if BCR and/or TLR responses facilitate 
autoantibody production.  Our studies of TLR-mediated responses in Sm-, HEL- and 
Ars/A1-specific autoreactive B cells identify DCs and MΦs as key regulatory cells during 
innate immune responses, and show that DC-mediated tolerance is defective in lupus-
prone MRL/lpr mice.  These findings implicate dysregulated innate immune responses in 
the autoantibody production associated with SLE.  
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Figure 2.1. The distribution of splenic myDCs and MΦs are comparable between B6 
and MRL/lpr mice.  DC and MΦ subsets were separated based on CD11c and CD11b 
expression. Dot plots are representative of nine mice each. 
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Table 2.1.  The frequencies of splenic myDCs and MΦs are not diminished in 
MRL/lpr mice.a
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Figure 2.2. DCs from MRL/lpr mice fail to efficiently repress Sm-specific Ig 
secretion.  LPS-stimulated (30 μg/ml) splenocytes (1x105 B cells) or purified B cells 
(1x105) were cocultured with the indicated ratios of BMDCs (A), or ex vivo splenic DCs 
(B).  Secreted IgMa/κ levels were quantitated by ELISA from the day 4 culture 
supernatant.  LPS-stimulated purified B cells (100%) secreted 1-10 μg/ml IgMa/κ. Data 
represent 14 (A) and 8 (B) MRL/lpr mice. (SControls, Q B6, MRL/lpr). 
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  Figure 2.3. DCs from MRL/lpr mice are defective in IL-6 secretion upon TLR4, 7 
and 9 stimulation, but not upon TLR3 stimulation.  1x104 BMDCs (A), or 1x105 ex 
vivo splenic DCs (B), were stimulated with LPS (30 μg/ml).  5x105 BMDCs were 
stimulated with poly (I:C) (50 μg/ml) (C), R848 (10 μg/ml) (D), and non-CpG ODN 
(/) or CpG ODN (Q / )(1μg/ml) (E).  IL-6 was quantitated by ELISA from the day 
4 culture supernatants. Data represent at least 5 mice per group.  (Q B6, MRL/lpr, 
▲MRL, UB6.lpr, NZM2410, NZBxNZWF1)  
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Figure 2.4. MyDCs from B6 and MRL/lpr mice have similar levels of TLR4 surface 
expression and no difference in survival.  MyDCs within the CD11c+ splenocyte 
population were gated as CD11chi/CD11bint/hi, and then analyzed for TLR4 expression 
(A).  LPS-stimulated BMDCs were stained with 7-AAD on Day 4 (B).  The thick black 
line represents B6 mice.  The thin gray line represents MRL/lpr mice. Histogram shows a 
representative plot from three experiments. 
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Figure 2.5. DCs from MRL/lpr mice show a decrease in synthesis and ability to 
sustain IL-6 mRNA levels.  Real time-PCR was performed on RNA isolated from LPS 
stimulated BMDCs (A) untreated or (B) treated with DRB at the indicated timepoints.  
The data from three individual B6 (Q) and six MRL/lpr () mice are plotted as %18S. 
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Figure 2.6. DCs from MRL/lpr mice fail to activate NF-κB and AP-1.  BMDCs were 
stimulated with LPS (15 μg/ml) for the indicated times.  Nuclear extracts were prepared, 
and NF-κB/DNA binding (A) or AP-1/DNA binding (D) was assessed by EMSA. 
Nuclear extracts prepared from unstimulated B6 BMDCs (lane 1) or from DCs stimulated 
6 hours with LPS (lanes 2-4) were incubated with radiolabeled DNA probe (lanes 1-4), 
unlabeled competitive DNA (lane 3), or mutant DNA (lane 4), and NF-κB DNA binding 
was assessed by EMSA (B).  NF-κB/DNA complexes in the nuclear extracts from 
unstimulated B6 DCs (lane 1) or from DCs stimulated 6 hours with LPS (lane 2-5) were 
supershifted using p65 (lane 3), p50 (lane 4), or c-Rel antiserum (lane 5) (C). 
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Figure 2.7. TLR4-stimulated DCs from MRL/lpr mice are unable to sustain IκBα 
phosphorylation.  BMDCs (2x106) from B6 and MRL/lpr mice were stimulated with 
LPS (15 μg/ml) (A) or poly (I:C) (50 μg/ml) (B) for the indicated timepoints.  Phospho-
IκBα, IκBα, and β tubulin (A) or actin (B) expression in whole cell lysates was 
determined by immunoblotting.  Data represent 7 (A) and 3 (B) experiments. 
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Figure 2.8. In addition to IL-6, other soluble factors regulate autoantibody 
secretion. Purified B cells (1x105) from 2-12H/Vκ8 mice were stimulated with LPS (30 
μg/ml) in the absence (S) or presence of DC CM (25% of final volume) from B6 (Q) or 
MRL/lpr () mice (A). DC CM from individual MRL/lpr mice () was untreated or 
neutralized with anti-IL-6 antibody (50 μg/ml) prior to coculture with B cells from 2-
12H/Vκ8 mice (B). 5x104 purified B cells from 2-12H/Vκ8 and B6 mice were stimulated 
with LPS (30 μg/ml) in the absence (S) or presence of DC CM from B6 (Q) or MRL/lpr 
() mice (C). Secreted IgMa/κ levels were quantitated by ELISA from the day 4 culture 
supernatant. LPS-stimulated purified B cells (100%) secreted 1-10 μg/ml IgMa/κ. Data 
represent 15 (A), 5 (B), and 4 (C) MRL/lpr mice. 
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Chapter III.  Dendritic cells and macrophages repress innate and 
adaptive B cell responses coincident with the display nuclear self-
antigen. 
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Abstract 
B cell tolerance during innate immune responses requires chronic exposure to self-
antigen to allow IL-6 and CD40L to repress Ig secretion.  In this report, we show that 
murine B cells (2-12H/Vκ8) specific for the nuclear self-antigen Smith (Sm) fail to 
repress LPS-induced Ig secretion when chronically exposed to soluble Sm, small nuclear 
ribonucleoprotein particles (snRNPs), or apoptotic cells.  Instead, these B cells recognize 
self-antigen displayed on the surface of dendritic cells (DCs) and macrophages (MΦs) as 
evidenced by constitutive destabilization of the BCR complex.  The display of nuclear 
self-antigen by DCs and MΦs is not limited to Sm as DNA and histones are also present.  
In assessing if these self-antigens were functional in regulating Ig secretion we 
discovered a contact-dependent mechanism of regulating Ig seretion that occurs 
independent of BCR engagement of self-antigen.  In addition, autorective and naïve 
BCR-mediated signaling is repressed by DCs.  Collectively, our data demonstrate that 
innate and adaptive immune responses of B cells are regulated by DC independent of the 
nuclear self-antigen displayed on their surface.
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Introduction 
The dysregulation of B cells specific for nuclear antigens is a hallmark of many 
autoimmune diseases.  Nuclear antigens become accessible to the immune system when 
they are displayed on the surface of apoptotic cells or released as soluble proteins upon 
cell lysis (11, 13, 14, 221).  How different forms of nuclear self-antigens induce B cell 
tolerance remains unclear; however, the strength of the BCR signal and the availability, 
and/or location of antigen directly affects the differentiation of autoreactive B cells in 
antibody secreting cells (131, 180, 222, 223).  This is exemplified in the hen egg 
lysozyme (HEL) model of B cell tolerance where, BCR interaction with soluble HEL 
produce anergic B cells while membrane bound HEL causes deletion of autoreactive B 
cells (224).   Further, in nuclear antigen-specific models, an increased burden of apoptotic 
cells is implicated in autoimmune disease, and injection or accumulation of apoptotic 
cells activates some autoreactive B cells, including Smith antigen (Sm)-specific B cells 
(13, 15, 177).  Depending on the affinity of the BCR for antigen Sm-specific B cells are 
regulated by B1 cell formation or peripheral anergy, (137, 140).  However, since B cell 
anergy requires tolerizing antigen to constantly occupy the BCR (136), it remains unclear 
how the low concentration of soluble small nuclear ribonucleoprotein particles (snRNPs) 
or the transient appearance of apoptotic cells regulate Sm-specific B cells. 
 
During innate and adaptive immune responses, autoreactive B cells are regulated by 
multiple mechanisms.  Sm-specific B cells are regulated during innate immune responses 
through IL-6 and CD40L secreted by DCs and/or MΦs (103, 104).  HEL-specific B cells 
repress TLR9-induced Ig secretion by constitutive ERK activation resulting from chronic 
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exposure to high-affinity self-Ag (220).  In another model, immune complexes induce B 
cell proliferation when the BCR and Toll Like Receptor-9 or 7 (TLR9, TLR7) are 
coligated, yet antigen alone fails to initiate a response (55, 92).  During adaptive immune 
responses, autoreactive B cells remain unresponsive to self-antigen by modulating 
surface BCR levels (180), inducing B1 cell formation (131), failing to obtain T cell help 
(130), and desensitizing the BCR to renewed signal transduction (132).  In addition, 
antigen destabilizes the BCR complex (μm/Ig-α/β), dissociating Ig-α/β from μm by 
distances of approximately 200 nm (133, 134).  The observation that BCR destabilization 
occurs following receptor ligation suggests it contributes to the unresponsive state of 
autoreactive B cells (135).  Thus, multiple mechanisms have evolved to regulate 
autoreactive B cells stimulated by self-antigen or TLR ligation.  
 
In this report we show that some soluble self-antigens effectively repressed LPS-induced 
Ig secretion, while nuclear self-antigens such as Sm, SnRNPs, and apoptotic cells failed 
to tolerize autoreactive cells.  Analysis of other possible sources of tolerizing antigen 
revealed that DCs and MΦs displayed endogenous nuclear self-antigens including Sm, 
DNA and histones.  Since soluble mediators secreted by DC/MΦs repress autoantibody 
secretion during the innate immune responses, we hypothesized that this surface-antigen 
might also be tolerogenic.  However, in the absence of soluble factors, we found that Ig 
secretion by autoreactive B cells is repressed through a contact-dependent mechanism, 
independent of BCR ligation.  Sm-specific B cells recognized the self-antigen displayed 
on DC/MΦs demonstrated by their destabilized BCR.  However, DCs were not able to 
induce BCR signaling in Sm-specfic B cells.  Indeed, these cells repressed BCR-mediated 
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signal transduction in both autoreactive and naïve B cells.  The data show that although 
Sm-specific B cells recognize self-antigen on the surface of DC/MΦs, contact mediated 
repression of the innate and adaptive immune response occur independent of BCR 
engagement of antigen. 
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Materials and Methods 
Mice  
2-12H/Vκ8/Cκ-/- immunoglobulin transgenic mice were previously described (225). 
sHEL (ML5) mice, HEL-Ig x sHEL (MD4 x ML5) and C57BL/6 (B6) mice were 
purchased from Jackson Laboratory.  Animals were used at 8-16 weeks of age and 
maintained in an accredited animal facility. 
 
Reagents and Abs  
Antibodies to CD3, CD19, CD69, CD11c, CD11b, and phosphorylated -tyrosine were 
obtained from BD Biosciences, canine distemper virus (CDV) from Biodesign, IgM Cy3 
and IgG Cy3 from Jackson ImmunoResearch, phosphorylated-Syk from Cell Signaling 
and Streptavidin Alexa 465 and 647 from Molecular Probes.  Sm was obtained from 
Immunovision.  2.12.3 and Vκ31T were gifts from Steve Clarke (University of North 
Carolina, Chapel Hill, NC), and PA4 and LG2-2 gifts from Marc Monestier (Temple 
University, Philadelphia, PA).  2.4G2, HO13, B7.6 (anti-μ), and anti-HEL (HyHEL10) 
were purified from hybridoma supernatant. 
 
B cell purification and culture 
Resting B cells (ρ>1.066) were isolated by percoll density centrifugation as previously 
described (133). Splenic B cells were purified by negative selection (Stem Cell 
Technologies) as previously described (225) and cultured with LPS and Sm, snRNPs or 
apoptotic cells for 4 days. 
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Preparation of DCs and MΦs 
Preparation of BMDC/MΦs was performed as previously described (225).  CD11c+ 
splenocytes were purified by positive selection (Miltenyi Biotech). 
 
Apoptotic cells 
Apoptotic cells were prepared by irradiating thymocytes with 600 rads and culturing 
overnight.  After co-culture with DCs they were removed by lympholyte-m (Cedarlane) 
density centrifugation.  
 
ELISA  
Quantitation of IgMa/κ was described previously (225).  Ig levels were plotted as "percent 
control” calculated as the percent secretion relative to LPS-stimulated B cells.  
 
Immunoprecipitation and immunoblotting   
BCR destabilization was detected as previously described (133).  B cells (3x106) were 
stimulated with anti-m or BMDC solublized in lysis buffer containing 1% NP-40 lysis 
buffer.  Proteins were resolved by SDS-PAGE.  Phosphorylated-IkBa and 
phosphorylated-Syk were immunoblotted with HRP tagged antibodies and detected by 
chemiluminescence (GE Biosciences).   Densitometry was performed utilizing Image J 
(National Institute of Health).  Briefly, we multipled the area by the density and 
subtracted the background. 
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Immunofluorescence staining 
1x106 B6 BMDC/MΦs, CD11c+ splenocytes, T cells, or B cells were stained with Vκ31T (anti-
Sm), 2.12.3 (anti-Sm), LG2-2 (anti-histone), PA4 (anti-DNA) or isotype controls (HO13 or 
CDV) followed by fluorochrome-conjugated secondary antibodies.  BMDC/MΦs were treated 
with trypsin (2.5 mg/ml) or DNase (25 μg/ml) prior to PA4 staining.  Cells were plated onto 
coverslips and images obtained using the Zeiss Axioplan 2 fluorescence microscope or the 
Olympus Fluoview 500 microscope and deconvolved using SlideBook (Intelligent Imaging 
Innovation) and/or Image J (NIH).  
 
Statistical Analysis 
Student’s t test was used.  Values of p < 0.05 were considered significant and denoted by an 
asterisk (*). 
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Results 
Soluble self-antigens and apoptotic cells do not tolerize Sm-specific B cells. 
Previous data demonstrate that autoreactive B cells must be chronically exposed to self-
antigen for tolerance mechanisms to regulate innate immune responses (103, 104).  
However, the location and form of the self-antigens that tolerize these cells remains 
unclear.  To determine if some self-antigens are sufficient to regulate B cell responses we 
LPS-stimulated HEL-specific B cells cocultured with cognate antigen (Figure 3.1A).  
Purified B cells from HEL-Ig x sHEL mice secrete Ig upon LPS stimulation because they 
were disengage self-antigen during the purification (226).  However, LPS-induced Ig 
secretion is completely repressed when HEL antigen is present (Figure 3.1B) (220, 225).  
This corroborates that self-antigen regulates TLR responses (220, 226).  To determine if 
any of the known forms of Sm regulate TLR-induced Ig secretion, we LPS-stimulated 
Sm-specific B cells (2-12H/Vκ8) in the presence of soluble Sm, snRNPs, and apoptotic 
cells, then assessed autoantibody secretion.  Figure 3.1B demonstrates LPS-induced Ig 
secretion was unaffected by the presence of soluble Sm or by the snRNP complex.  In 
contrast, Sm on the surface of apoptotic cells enhanced Ig secretion (13, 15).  These data 
indicate that some self-antigens fully regulate TLR responses, but that in the case of Sm, 
the known forms of Sm are either ignored, or induce B cell activation.   
 
Nuclear Self-Antigen is Displayed on DC/MΦs 
DC and MΦs are responsible for clearing apoptotic cells.  Since apoptotic cells display 
nuclear self-antigen on their surface, we hypothesized that DC/MΦs might acquire self-
antigens from apoptotic cells during phagocyotsis providing a source of tolerizing antigen 
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while simultaneously colocalizing DC/MΦs with autoreactive B cells to allow soluble 
mediators to repress autoantibody secretion (103).  To investigate this possibility, we 
stained BMDCs, BMMΦs, and CD11c+ splenocytes for Sm.  As demonstrated in Figure 
3.2, BMDCs, BMMΦs, and ex vivo CD11c+ cells showed the presence of surface Sm.  
Trypsin treatment removed the antigen, indicating that Sm was displayed as a surface 
protein.  To confirm the specificity of the anti-Sm antibody for Sm, we absorbed the 
antibody with recombinant Sm.  As shown in Figure 3.2, antibody absorbed with Sm 
failed to stain BMDCs while antibody absorbed with BSA stained these cells.  These data 
indicate that the anti-Sm antibody recognizes Sm on DCs and MΦs. 
 
Previously, others reported that histones and DNA were present on the surface of 
apoptotic cells (14).  If Sm displayed by DCs and MΦs originated from apoptotic cells, 
we reasoned that other nuclear antigens might also be present.  To assess this, BMDCs 
and BMMΦs were stained with antibodies to DNA and histones.  As shown in Figure 3.3, 
BMDCs and BMMΦs displayed histones and DNA on their surfaces.  Further, treatment 
of cells with DNase abrogated staining, confirming the specificity of the antibody and 
that the antigen was located on the cell surface.  The data show that several nuclear self-
antigens are displayed on the surface of DCs and MΦs.  
 
To address if apoptotic cells are a source of the nuclear self-antigen found on the surface 
of DC/MΦs, BMDCs were cultured with apoptotic cells, the dying cells were removed by 
density centrifugation, and the DCs were stained for DNA.  We observed that after 
coculture with apoptotic cells, DCs displayed a two-fold (p=0.002) increase in DNA on 
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their surface compared to untreated cells (Figure 3.4A).  This shows that apoptotic cells 
are a source of nuclear self-antigen for display on the surface of DC/MΦs.  The 
observations that nuclear self-antigens are displayed by DCs and MΦs raised the 
possibilities that other cells may display self-antigen and that all self-antigens, regardless 
of source, might be present on these cells.  To address the first possibility, splenic T and 
B cells were sorted for the expression of CD3 or B220 and then stained for surface Sm.  
As shown in Figure 3.4B, neither T nor B cells displayed surface Sm.  To assess if all 
self-antigens were displayed on DCs and MΦs, we stained the CD11c+ splenocytes from 
mice expressing a HEL transgene (ML5).  These mice constitutively secrete HEL with 
serum levels approximating 15 ng/ml, levels sufficient to induce a state of 
unresponsiveness in HEL-specific B cells.  As shown in Figure 3.4C, CD11c+ 
splenocytes failed to display the soluble antigen, HEL, on their surface.  This was not due 
to the failure of the anti-HEL antibody to recognize HEL because loading exogenous 
HEL onto a HEL-specific B cell line (K46/D1.3) resulted in HEL-specific staining.  The 
data indicate that nuclear, but not soluble, self-antigens are displayed by DCs and MΦs, 
but not by lymphocytes.  
 
B cell coculture with DCs leads to activation. 
It has been previously demonstrated that intact antigen exogenously loaded onto DCs 
causes BCR-mediated signal transduction (65, 165, 166, 167).  DC/MΦs regulate 
chronically antigen-experienced B cells during innate immune responses and display 
nuclear self-antigen on their surface, therefore, we hypothesized that this form of self-
antigen might tolerize Sm-specific B cells.  Alternatively, in the absence of functional 
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tolerance mechanisms, the antigen on the DC/MΦs might activate Sm-specific B cells 
and promote autoimmunity.  To first assess if DCs had any effect on B cell responses, we 
cocultured B cells with DCs and monitored downstream responses.  As shown in Figure 
3.5A, B6 cells cocultured with DCs increased IκBα phosphorylation after five minutes. 
Similarly, autoreactive B cells upregulated CD69 when cocultured with DCs for six hours 
(Figure 3.5B).  This effect was also apparent when B6 (non-autoreactive) B cells were 
cocultured with DCs, indicating that DCs interact with B cells inducing B cell responses 
that are independent of surface antigen binding to the BCR.  The finding that B6 B cells 
were activated by DCs suggested that activation might be induced through TLRs since 
the percent of autoreactive B cells in the polyclonal repertoire of B6 mice would be very 
small.  Thus, it was unclear if BCR and/or TLR-mediated responses activated 2-12H/Vk8 
B cells. 
 
BCR-mediated signal transduction is not induced by coculture with DCs. 
BCR or TLR ligation induces antibody secretion by B cells.  To test if DCs activate B 
cells through the BCR we monitored the ability of DCs to induce Syk phosphoryation 
since this effect is only activated upon BCR ligation (Figure 3.6 A).  Given that marginal 
zone (MZ) B cells to undergo rapid BCR-mediated responses we chose to use the 2-12H 
model because it contains this population.  Purified 2-12H B cells do not exhibit 
detectable Syk phosphorylation in the absence of stimulation.  In contrast, anti-μ induces 
robust Syk phosphorylation demonstrating that the cells are capable of responding to 
BCR ligation.  Addition of DC/MΦs failed to induce detectable Syk phosphorylation, 
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suggesting that the display of Sm on the DC/MΦs does not activate BCR-mediated signal 
transduction.  
 
To define if the absence of Syk phosphorylation was due to our inability to detect low 
level signals we examined if a downstream consequence of BCR signaling was evident. 
During adaptive immune responses, one consequence of BCR-mediated signal 
transduction is the accumulation of intracellular μ.  FO and MZ B cells from 2-12H mice 
cocultured with DCs for 12 or 24 hours failed to exhibit increased intracellular μ (Figure 
3.6B).  This corroborates the lack of Syk phosphorylation and suggests that the Sm 
antigen displayed on the DC fails to elicit BCR-mediated signal transduction.  However, 
it raised the possibility that DCs might actively inhibit BCR- and/or TLR-derived 
responses.   
 
DCs repress LPS-induced Ig secretion in a contact-dependent mechanism. 
To determine if DCs repress innate responses by mechanisms other than the secretion of 
soluble mediators, we assessed if their contact with autoreactive B cells regulated 
secretion.  TLR4-deficient DCs in contact with autoreactive B cells repressed 50% of 
LPS-induced Ig (Figure 3.7A).  However, the ability of DCs to repress Ig secretion was 
abolished when the B cells were separated from the DCs in a transwell apparatus 
indicating a contact-dependent mechanism of repression.  To evaluate if the antigen 
displayed by the DCs was essential for contact-dependent repression, we blocked the Sm 
on the surface of the TLR4-deficient DCs with an anti-Sm F(ab’)2.  Blocking surface Sm 
on TLR4-deficient DC did not change the levels of LPS-induced Ig secretion (Figure 
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3.7B).  This indicates that contact-dependent regulation of TLR-induced Ig secretion is 
independent of BCR engagement by self-antigen.  To further clarify if surface antigen on 
the DC regulates LPS-induced Ig secretion we tested if LPS-induced Ig secretion by 
HEL-specific B cells was repressed by DCs.  Because DCs do not display HEL antigen, 
we reasoned that if contact-dependent regulation of innate responses was mediated in an 
antigen-independent manner, HEL-specific B cells would be repressed by TLR4-deficient 
DCs.  As shown in Figure 3.7C, TLR4-deficient DCs repressed 50% of Ig secretion by 
LPS-stimulated HEL-Ig x sHEL B cells. Collectively, the data show that nuclear self-
antigens are displayed on the surface of DCs, however, they repress Ig secretion during 
innate immune responses in a contact-dependent manner that is independent of antigen 
binding to the BCR.    
 
DC/MΦs induce Sm-specific BCR destabilization. 
Although the data identify a novel contact-dependent mechanism of repression of Ig 
secretion, the regulation of the innate immune response was found to be independent of 
the BCR ligation of antigen.  However, it was unclear if surface-antigen on DC/MΦs 
affects B cell responses.  The unresponsive state that protects autoreactive B cells from 
dysregulated adaptive immune responses requires the BCR to be constantly occupied by 
self-antigen (136).  A consequence of constant receptor occupancy in low-affinity B cells 
is destabilization of the BCR.  We reasoned that if 2-12H/Vk8 B cells constitutively 
recognized Sm on the DC, receptor destabilization might be evident.  We assessed the 
amount of Ig-α/β associated with μm in B cells from 2-12H/Vκ8 mice compared to B 
cells from control mice (Vκ8 transgenic).  We utilized B cells copurified with DC/MΦs 
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by T-depletion and density centrifugation or highly purified B cells with less than 5% 
contaminating DC/MΦs obtained by negative selection.  Splenic B cells isolated by 
negative selection showed stoichiometric amounts of Ig-α/β coprecipitated with μm 
indicating that they display an intact BCR (Figure 3.8; left panel).  In contrast, B cells 
purified by T cell depletion and density centrifugation consistently showed a two-fold 
(p=0.01) decrease in the amount of coprecipitated Ig-α/β in μm immunoprecipitates, 
signifying destabilization of the receptor complex when DCs and MΦs are present 
(Figure 3.8; right panel).  Previous studies identified that BCR-derived signals are 
required for destabilization, indicating that Sm-specific B cells encounter self-antigen on 
the surface of DC/MΦs, thus inducing BCR destabilization (133).  Combined with the 
data in Figure 3.6, a model emerges wherein an autoreactive B cell recognizes antigen 
and destabilizes Ig-α/β from μm but do not elicit detectable positive signals via the BCR.  
This suggested the possibility that DCs may actively inhibit BCR-derived signals. 
  
DCs negatively regulate BCR-dervied signaling. 
Signal transduction through the BCR is regulated at multiple levels but coligation of 
inhibitory receptors sets the threshold of BCR signaling and protects from prolonged 
signaling.  If DCs actively inhibit BCR signal transduction anti-μ induced Syk 
phosphorylation would decrease when DCs were present in the B cell cultures. 
Preincubation of 2-12H B cells with B6 BMDCs lead to a two-fold (p=0.01) reduction in 
anti-μ-induced Syk phosphorylation, establishing that DCs inhibit BCR signaling in 
autoreactive B cells (Figure 9A).  To assess if DC-mediated repression was exclusive to 
autoreactive B cells we induced Syk phosphorylation in B6 B cells after incubation with 
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DCs.  As shown in Figure 9B, DCs also repressed BCR-mediated signaling in B6 B cells 
by a two-fold reduction (p< 0.0001).  This is the first evidence that DCs negatively 
regulate BCR signal transduction and raised the possibility that ligands for inhibitory 
receptors were selectively expressed on DC/MΦs, thereby regulating basal and antigen-
induced signaling thresholds.  Collectively, the data show that although DCs and MΦs 
provide a unique source of self-antigen to B cells as demonstrated by destabilization of 
the BCR.  We cannot define if this antigen tolerizes or activates autoreactive B cells 
because a cell contact-dependent inhibitory mechanisms precludes such analysis.   
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Discussion 
The regulation of low-affinity autoreactive B cells during innate immune responses 
requires DCs and MΦs to secrete IL-6, TNF- α, and CD40L ((103, 104) Gilbert MR and 
Vilen BJ manuscript in preparation).  These soluble mediators repress LPS-induced Ig 
secretion by B cells chronically exposed to self-antigen, but not acutely-stimulated, naïve 
B cells.  In this report, we show that DCs and MΦs display nuclear self-antigens that 
were recognized by autoreactive B cells.  DNA, histones, and Sm were found on the 
surface of CD11c+ splenocytes and BMDC/MΦs, suggesting that their display in vivo 
was constitutive.  Apoptotic cells were a source of antigen to the DCs because their 
coculture resulted in increased surface antigen.  Although several nuclear self-antigens 
were present on DCs and MΦs, a soluble antigen, HEL, was not evident. This 
demonstrates that not all self-antigens are displayed on DCs and MΦs.  BCR 
destabilization of Sm-specific B cells indicates recognition of the endogenous antigen on 
the surface of DC/MΦs; however, there is no evidence of BCR-mediated signal 
transduction.  Indeed, the DCs are repressive of BCR mediated signaling and Ig secretion 
resulting from LPS stimulation in a manner independent of BCR engagement of antigen. 
 
The data indicate that the DCs repress both the adaptive and innate immune responses.   
However, there is still much to understand about these mechanisms.  It is of interest to 
assess if the repression of BCR signaling is contact-dependent and how this affects BCR 
induced Ig secretion.  We know that contact is essential in regulating the innate immune 
response, but it is unclear if this mechanism exclusively affects chronically antigen-
experienced autoreactive B cells or if it also affects naïve B cells.  The repression of BCR 
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signaling suggests that inhibitory receptor(s) might be involved.  It is unclear if the same 
receptor(s) would regulate the TLR stimulated cells because few studies have addressed 
the role of inhibitory receptors in innate responses.  Defining the molecular mechanisms 
of the DC-mediated repression will also further our understanding of the role for surface 
self-antigen.   
 
Despite the interaction of the Sm-specific B cell and the antigen on the surface of 
DC/MΦs, there was no detectable signal transduction.  BCR destabilization has been 
shown to cause receptor desensitization in vitro, therefore, the lack of signaling could be 
from prolonged interaction with nuclear self-antigen in vivo (65, 165, 166, 167). The lack 
of BCR mediated signaling in Sm-specific B cells raised several other possibilities.  First, 
that the BCR may be of such low affinity that the antigen is recognized but it does not 
transduce a signal.  Second, the signal is below the limit of detection.  Third, the DC is 
actively repressing the B cell from signaling.  While investigating these possibilities we 
discovered that the pre-treatment of non-transgenic, B6 and Sm-specific 2-12H B cells 
with DCs resulted in decreased phosphorylation of Syk after stimulation of the BCR.   
Thus, DCs repress BCR-mediated signal transduction in both autoreactive B cells and 
naïve cells.  It is unclear what is the importance of DC-repression of non-autoreactive B 
cells is in the adaptive immune response.  In vitro can repress naїve B cell signaling.  
However, in vivo this regulation may only occur when DCs and B cells encountered each 
other for prolonged periods of time as a result of the autoreactive BCR engaging its 
cognate endogenous antigen on the surface of DC/MΦs.  Thereby, facilitating the 
inhibition conferred by the DC.  This regulation of B cell signaling is yet to be 
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understood, but could have broader implications in the maintenance of tolerance.   
Collectively these data show that DC/MΦs can regulate both the adaptive and innate 
immune responses.  
 
Nuclear self-antigens on the surface of DC/MΦs are recognized by autoreactive B cells 
and induce BCR destabilization.  Using high-affinity antigen-pulsed systems, several 
groups reported that DCs displaying cognate antigen interact with B cells and transduce 
signals that promote class switching, and antigen processing (65, 165, 166, 167) . 
However, the physiological relevance of these antigen-pulsed DCs is unclear since we 
were unable to detect endogenous HEL on the surface of ex vivo CD11c+ splenocytes 
from mice expressing a HEL transgene (Figure 3.4B).  It is possible that DCs pulsed with 
HEL exhibit a much higher concentration of self-antigen compared to antigen displayed 
in vivo or that HEL expressed on CDllc+ splenocytes may be below our limit of detection.  
Jenkins et al, demonstrated that HEL-specific B cells could obatin with HEL antigen in 
the follicle without display on the surface of DCs (227).  Therefore, antigen loaded 
exogenously onto DCs may not represent a physiologically relevant mechanism of 
display.  
 
We demonstrated that apoptotic cells provide a source of antigen to DCs.  However, other 
antigens, such as immune complexes or soluble antigen, would be present in vivo and 
may also contribute to the antigen on the surface of these cells.  The mechanisms by 
which DC/MΦs acquire nuclear self-antigens remain unclear; however, a variety of 
surface receptors are used to clear apoptotic cells.  For example, immune complexes are 
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recognized by FcγRIIb and recycled to the DC surface (65).  Similarly, nuclear self-
antigens may be displayed on DC/MΦs via complement receptors since apoptotic 
antigens are readily coated with complement components (228, 229).  However, BMDCs 
from various mouse strains lacking complement component 4, FcγRIIb, or complement 
receptors 1, 2, or 3 display surface Sm (Carnathan DG unpublished observations).  One 
or a combination of receptors may be responsible for obtaining antigen and when one is 
deficient other receptors may compensate.  Another possibility is that donor cells transfer 
antigen to DCs through membrane lipids.  Others have reported that human DCs acquire 
HLA molecules by the transfer of membrane lipid from donor cell lines and transferred 
proteins activate tumor-specific CD4+ T cells (230, 231).  Apoptotic cells express surface 
self-antigen and DC/MΦs efficiently clear apoptotic debris, providing a possible mode of 
membrane transfer.  
 
The regulation of the innate and adaptive immune responses is important in maintaining 
B cell tolerance.  DCs repress LPS-induced Ig secretion through the secretion of 
repressive factors, IL-6 andCD40L, and by a contact-dependent mechanism.  Further, 
they are able to repress the BCR-mediated signal transduction in order to maintain 
unresponsiveness.  Therefore, we propose a model wherein antigen displayed by DCs and 
MΦs is recognized by the BC R, inducing destabilization, thus, prolonging the DC/MΦ 
interaction with the B cell.  This colocalization results in repression of both BCR-derived 
signaling as well as Ig secretion resulting from TLR-stimulation.  This ensures that low-
affinity autoreactive B cells maintain quiescence to self-antigen, such as apoptotic cells, 
and repress Ig secretion during innate immune response.  Lastly, chronic exposure to self-
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antigen reprograms IL-6 receptor and CD40L responses, allowing autoreactive and 
acutely-stimulated B cells to be differentially regulated by IL-6 and CD40L.  This 
promotes immunity in the absence of autoimmunity. 
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Figure 3.1.  Soluble Sm and apoptotic cells fail to negatively regulate Sm-speficic B 
cells. (A) Splenic B cells (1x105) purified by negative selection from HEL-Ig x sHEL 
mice were LPS stimulated (30 μg/ml) in the presence or absence of soluble HEL (100 
μg/ml) (B) 2-12H/Vκ8 B cells (1x105), purified by negative selection, were LPS 
stimulated (30 μg/ml) in the presence or absence snRNPs (10 μg/ml), soluble Sm (10 
U/ml) or apoptotic cells (5x105).  Ig secretion was quantitated by ELISA at day 4. 
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 Figure 3.2. BMDCs, BMMΦs, and CD11c+ splenocytes display surface Sm. B6 
BMDCs (A, B), BMMΦs (C, D), and CD11c+ splenocytes (E, F) were untreated or 
trypsin treated, then stained with anti-Sm (2.12.3).  Forty-six percent of untreated 
BMDCs, 44% of untreated BMMΦs, and 40% of untreated CD11c+ splenocytes 
displayed Sm (100 cells analyzed).  In contrast, 2% BMDC/MΦs and 4% CD11c+ cells 
showed Sm following trypsinization. BMDCs (G, H) were stained with anti-Sm absorbed 
with BSA or recombinant SmD.  All images shown at a magnification of 63x. The insert 
contains a 1.5x magnification of a Sm-expressing CD11c+ cell. 
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 Figure 3.3. BMMΦs and BMDCs display surface histones and DNA. B6 ΒΜDCs (A-
D) and ΒΜΜΦs (E-H) were untreated or treated with DNase (D, H) and stained with 
isotype control (A, E), anti-histone (B, F), or anti-DNA (C, G).  Thirty-three percent of 
BMDCs and BMMΦs exhibited histone staining, 48% of BMDCs, and 44% of BMMΦs 
showed DNA (100 cells analyzed).  In contrast, 5% BMDCs and 7% BMMΦs displayed 
Sm following DNase treatment.  All images shown at a magnification of 63x. 
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Figure 3.4. Nuclear, but not soluble, self-antigens are displayed by DCs and MΦs, 
but not lymphocytes. (A) B6 BMDCs were cultured with apoptotic cells for 4 hours. 
The apoptotic cells were removed by density centrifugation and the cells were stained for 
the presence of DNA. The DCs cultured with apoptotic cells (right panel) displayed a 2-
fold (p=0.002) increase in antigen on their surface compared to DCs alone (left panel).  
(B) Sorted CD3+ splenic T cells and B220+ B cells were stained with anti-Sm.  (C) Ex 
vivo CD11c+ splenocytes (left panel) from mice expressing soluble HEL (ML5) were 
stained with anti-HEL. The HEL-specific D1.3 cell line (right panel) was loaded with 
HEL (500 ng/ml) and stained with anti-HEL.  Seventy-three percent of D1.3 cells 
displayed HEL (100 cells analyzed).  All images shown at a magnification of 63x. 
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 Figure 3.5. Coculture of DCs and B cells leads to B cell activation. (A) B6 B cells 
were stimulated with anti-μ or B6 BMDCs for 5 minutes.  The amount of 
phosphorylated- IκB-α in whole cell lysate was determined by immunoblotting. (B) 2-
12H/Vk8 (left panel) and B6 (right panel) purified B cells were stimulated with anti-
μ (dashed lines) or B6 BMDCs (thin line), or left unstimulated (thick line) for 6 hours.  
Cells were then stained with CD19 and CD69 and analyzed by flow cytometry. 
Immunoblots and histograms are representative of 3 experiments. 
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Figure 3.6. DCs do not induce BCR-mediated signal transduction in Sm-specific B 
cells. (A) Purified 2-12H B cells were stimulated with anti-μ or BMDCs for 5 minutes. 
The amount of phosphorylated-Syk in whole cell lysate was determined by 
immunoblotting.  (B) Purified 2-12H B cells were co-cultured with DCs and harvested at 
time points indicated.  Cells were fixed and stained for expression of intracellular 
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μ in MZ (top panels) and FO (bottom panels) B cells.  In both populations, B cells 
cultured with or with out DCs had the same amount of intracellular μ after 12 (left 
panels) and 24 hours (right panels).  Data is representative of 3 experiments. 
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Figure 3.7.  DCs repress LPS-induced Ig secretion by autoreactive B cells by an 
antigen- independent contact dependent mechanism.  (A)  2-12H/Vk8 B cells (1x105) 
were LPS stimulated (30 μg/ml) in the presence or absence of B6 or TLR4-deficient 
BMDCs (1x104) with or without a transwell apparatus. (B)  2-12H/Vk8 B cells (1x105) 
were LPS stimulated (30 μg/ml) in the presence or absence of B6 or TLR4-deficient 
BMDCs (1x104).  B cells were treated with TLR4-deficient DCs with or without anti-Sm 
F(ab’)2 (2.12.3) or isotype control murine IgG1 F(ab’)2.  (C)  HEL-Ig x sHEL B cells 
were LPS stimulated (30 μg/ml) in the presence or absence of B6 or TLR4-deficient 
BMDCs (1x104).  Ig secretion was quantitated by ELISA at day 4. 
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Figure 3.8. Sm-specific B cells recognize self-antigen and destabilize their BCR. The 
BCR complex was immunoprecipitated from 30x106 unstimulated,  B cells were isolated 
by either negative selection or by percoll density centrifugation (ρ>1.066).  Proteins 
resolved by SDS-PAGE were immunoblotted for μ-heavy chain and Ig-α.  For each 
purification method the intensity of Ig-α in 2-12H/Vκ8 relative to Vκ8 was determined 
by densitometry (displayed below each band).  Data is representative of 5 experiments. 
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Figure 3.9.  DCs repress BCR signaling upon anti-μ stimulation.  2-12H (A) or B6 
(B) B cells were cultured with or without B6 BMDCs for 1 hour and stimulated with anti-
μ for 5 min.  The amount of phophorylated-Syk in whole cell lysate was determined by 
immunoblotting followed by densitometry.  The 2-12H and B6 B cells cultured with DCs 
have two-fold (p=0.03) less p-Syk than B cells without DCs. The intensity of pSyk in B 
cells treated with DCs and anti-μ relative to B cells treated with anti-μ alone was 
determined by densitometry (displayed below each band).  Data is representative of 3 and 
5 experiments respectively. 
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CHAPTER IV.  DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulation of both the innate and adaptive immune responses is important in maintaining 
autoreactive B cell tolerance.  Microbial stimulation of TLRs provides a rapid 
inflammatory response involving the secretion of cytokines and production of antibodies.  
Further, B cell response to foreign antigen during the adaptive immune response is also 
essential in the clearance of infection.  However, the activation of autoreactive B cells by 
either self-antigen or microorganisms causes the production of autoantibodies and 
contributes to the development of autoimmune disease.  Therefore, SLE is characterized 
by hyperactive B cell activation resulting from abnormal tolerance mechanisms.   
 
We previously demonstrated that DCs repress LPS-induced Ig secretion by autoreactive 
B cells through soluble mediators.  Now we show that they can repress these B cells in 
the absence of soluble factors in a contact-dependent mechanism.  DCs from lupus-prone 
mice are defective in responding to LPS stimulation resulting in a deficient ability to 
repress the innate B cell response.  We also showed that DCs repress BCR-mediated 
signal transduction in naïve and autoreactive cells.  The mechanism of this repression is 
unknown, but one interesting possibility is an inhibitory receptor on the surface of B 
cells.  Our data show that DC/MΦs display nuclear self-antigen on their surface.  It is 
known that self-antigen is important in regulating B cell tolerance to antigen and 
microbial stimulation.  While the role of this antigen is unclear, we hypothesize that it is 
important in modulating autoreactive B cells susceptibility to regulation by soluble 
repressors and inducing colocalization.   
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The onset and later flares of autoimmune disease are often associated with bacterial or 
viral infection (76, 77, 78).  In particular, Epstein-Barr viral infection has been implicated 
in the onset and exacerbation of SLE (78).  Lupus-prone mouse models that are 
immunized with bacterial or viral components have aggravated symptoms (79, 80, 81).  
Further, several studies focusing on TLR-deficient mice and TLR expression in patients 
have demonstrated the importance of these receptors in the initiation and progression of 
the disease (85, 86, 87, 88).  Therefore, regulation of the innate immune response in 
autoreactive cells is critical in maintaining tolerance.  Previously, we described that 
DC/MΦs secrete IL-6 and CD40L and repress chronically antigen-experienced, 
autoreactive B cells; these B cells are then unable to secrete Ig in response to polyclonal 
activation (103, 104).  The cytokines produced by these cells are sufficient to repress Ig 
secretion by autoreactive B cells because the supernatant from stimulated cells or 
individual recombinant cytokines alone are repressive (103).  We studied this repression 
of innate responses in lupus-prone MRL/lpr mice to determine if this mechanism is 
dysregulated in disease.  Compared to B6 mice, the DCs from MRL/lpr were defective in 
their IL-6 mRNA production and secretion of IL-6 (Figure 2.3 and 2.5).  While overall 
the DCs were less efficient in their repression of Sm-specific B cells, their lack of IL-6 
production did not always correlate with deficient repression of Ig secretion (Figure 2.2).  
In order to make up for the lack of IL-6, other mechanisms of tolerance may be utilized.  
For instance, TNF-α, which is also secreted by DCs, represses Ig secretion by 
autoreactive B cells and, if produced at normal levels, could compensate for the defective 
production of other soluble mediators (Gilbert MR manuscript in preparation).  We also 
have demonstrated that in the absence of the tolerizing cytokines, DCs are able to 
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partially repress LPS-stimulated, autoreactive B cell secretion in a contact-dependent 
manner (Figure 3.7).  Cell contact-mediated inhibition of autoreactive B cells during an 
innate immune response is important when the DCs fail to be activated by the same 
pathogen as the B cell or are defective in secreting soluble factors as in the MRL/lpr 
mice.  However, because the MRL/lpr DCs have an overall defect in their ability to 
repress autoreactive cells, they may also lack the component(s) essential for the contact 
mediated repression, thereby exacerbating the lack of soluble repressors. Therefore, 
investigating the ability of MRL/lpr DCs to mediate contact-dependent repression will 
help us to fully describe their contribution to dysregulation of B cells in lupus-prone 
mice.  Our data confirm that the regulation of the TLR response in autoreactive cells is 
important in preventing their aberrant activation leading to the breakdown in tolerance 
and disease. 
 
Numerous studies characterize DCs as dysfunctional or abnormal in patients and lupus-
prone murine models.  We demonstrated MRL/lpr DCs compared to B6 were defective in 
the production of IL-6 mRNA and secretion of IL-6 upon LPS stimulation.  Because 
several components of the TLR4 signaling pathway were shown to be defective, we 
concluded that the diminished IL-6 production was due to dysfunctional TLR signaling 
(Figure 2.6 and 2.7).  Further, DCs were also defective in IL-6 production upon 
stimulation of TLR7 and 9, but not TLR3, indicating that the defect is in the MyD88-
dependent pathway (Figure 2.3).  We are unsure exactly where the dysregulation of 
signaling occurs.  It may be a defective component of the signaling pathway upstream of 
IκBα, or perhaps the receptor itself is unable to sustain the signal.  Signaling components 
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that act to repress TLR signaling may contribute to defective signal transduciton.  
Suppressors of cytokine signaling (SOCS) family proteins regulate TLR signaling (232).  
We have evidence that expression of SOCS3 is increased in MRL/lpr DCs (Gilbert MR 
unpublished observations).  Therefore, the response to TLR stimulation could be 
diminished due to overexpression or activation of repressive mediators.  DCs poor 
response to polyclonal activation might be due to an increase in apoptotic cells found in 
SLE (16, 17, 116, 161, 162).  DCs are responsible for the clearance of these cells, 
however, after phagocytosis they are not stimulated by polyclonal activation (199).  The 
antigen displayed on the surface of apoptotic cells may also contribute to defective TLR 
activation.  Exposure of cross-reactive TLRs 7 and 9 to self-antigen may desensitize the 
TLR signaling pathway (55, 89).  These receptors are not on the surface of the cell, but 
could interact with the antigen if it was endocytosed through another receptor delivered 
to the TLR endosome.  This could be mediated by receptors that are involved in 
phagocytosis, such as FcRs or complement (55).  Multiple factors may contribute to the 
dysregulation of TLR signaling.  The abnormal response of DCs to polyclonal activation 
leads to reduced cytokines secretion resulting in defective repression of autoreactive B 
cell Ig secretion. 
 
We demonstrated that the interaction between normal DCs and B cells results in 
repression of BCR-derived signaling in naïve and autoreactive B cells (Figure 3.9).  This 
is the first evidence that DCs repress BCR signal transduction.  Non-autoreactive B cells 
are sensitive to this repression; therefore, BCR desensitization by exposure to antigen is 
eliminated as a possible mechanism.  However, there are several other potential 
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mechanisms by which this repression could be mediated.  One interesting possibility is 
that DCs might activate inhibitory receptors on the surface of B cells that negatively 
regulate BCR signaling.  The inhibition by these receptors is mediated through the 
activation of protein phosphatases such as SHP-1, SHP-2, and SHIP.  CD72, PIR-B, CD5 
and CD22 associate with SHP-1 to attenuate BCR-derived signals (233, 234, 235, 236).  
FcγRIIb activates SHIP and PD-1 and PIR-B recruit SHP-2 to prevent downstream 
signaling from the BCR (235, 237, 238).  Of particular interest are CD22 and FcγRIIb, 
because of their involvement with Lyn (106, 239).  Lyn has been shown to be able to 
repress both BCR- and TLR-mediated responses (240, 241).  In this scenario, DC-
mediated repression of the innate and adaptive immune responses could be mediated 
through the same receptor.   
 
In order for this regulation to occur through one of these inhibitory molecules, the DC 
must engage the receptor on the B cell.  If the antigen on the surface of DCs is in IC, then 
FcγRIIb would be a candidate for repression.  The receptors CD22, CD72, Plexin B-1, 
PIR-B, and PD-1 have known ligands on the surface of DCs (237, 242, 243, 244, 245, 
246, 247). However, not all of the ligands for these inhibitory receptors have been 
identified.  There may be an unknown receptor-ligand combination that promotes 
negative regulation of the BCR when in contact with the surface of DCs.  It is also 
thought that some receptors and ligands for negative regulation are both present on the 
surface of the B cell and can interact in cis (248, 249).  Instead of providing a ligand, the 
DC may act as a bridge to bring these two molecules together.  Because several of these 
receptors utilize the same phosphatases, multiple receptors may be involved.  
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Determining if inhibitory receptors are involved in DC-mediated repression of BCR 
signaling will further our understanding of this mechanism.  
 
Another reason that inhibitory receptors are potential candidates for this repression is that 
several of the molecules discussed above have been implicated in the development of 
autoimmune disease.  The expression of FcγRIIb, CD72, and Lyn is reduced in murine 
lupus models and in patients, which results in activated B cells (62, 63).  Mice lacking 
FcγRIIb, CD22, and Lyn develop disease (27, 240).  We would like to investigate if 
lupus-prone DCs can mediate this general repression of BCR signaling and if lupus-prone 
B cells are susceptible to it.  The ability of DCs to repress BCR signal transduction 
implies that it could be important in regulating autoreactive B cells’ response to cognate 
antigen to prevent an autoimmune response 
 
We demonstrated that naïve B cell signaling is also negatively regulated by DCs (Figure 
3.9).  Repression of both naïve and autoreactive B cells was not complete.  It was 
diminished by half compared to B cells stimulated with anti-μ alone.  It is possible that 
the DCs are only regulating a specific population of B cells.  Another potential role for 
this repression is that DCs may provide a developmental checkpoint by increasing the 
threshold of stimulation for the cognate antigen.  This mechanism could prevent B cells 
from becoming antibody secreting cells.  Therefore, it is important to examine if DCs can 
repress antigen-induced Ig secretion and proliferation in both autoreactive and naïve B 
cells.  These studies will help us to determine the role for DC-mediated repression of 
BCR-signal transduction.   
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 The ability of DCs to display intact antigen resulting in prolonged interaction with B cells 
has been demonstrated in a variety of studies.  DCs exogenously loaded with HEL cause 
antigen-specific B cells to signal (165, 166, 167).  Follicular DCs hold IC on their surface 
in germinal centers to prevent apoptosis and promote proliferation of B cells (250, 251).  
Blood DCs capture and transport antigen to interact with splenic MZ B cells and help 
induce the T-independent immune response (188).  These data indicate that DCs activate 
B cells by providing a cognate antigen. However, HEL-specific B cells can bind to 
soluble antigen in the follicle without DCs (227).  Further, most of these studies 
examined exogenously-loaded, high-affinity antigens, infectious antigens, or synthesized 
immune complexes. Our confocal studies demonstrate that endogenous, nuclear self-
antigen is constitutively displayed on the surface of DC/MΦs (Figure 3.2 and 3.3).  Low-
affinity Sm-specific B cells can recognize Sm on the surface of DC/MΦs, demonstrated 
by their destabilized BCR (Figure 3.8). However, this interaction does not result in 
activation or BCR signaling as it does in the studies described above (Figure 3.6).  
Because DC/MΦs display nuclear antigens other than Sm, such as DNA and histones, it 
would be of interest to study the stability of BCRs in other autoreactive B cell models, 
specifically Ars/A1 that recognizes ssDNA and VH3H9H that have anti-ss and dsDNA B 
cells (181, 252).  This would confirm that other nuclear antigens on the surface of 
DC/MΦs can induce a similar response.  If multiple autoreactive cells recognize low 
affinity self-antigens, it would corroborate the idea that the DCs and autoreactive B cells 
maintain contact with each other.  Further, we hypothesize that the antigen is important in 
colocalizing DC/MΦs and autoreactive B cells specific for nuclear antigen in order to 
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mediate repression to both antigen and infectious stimuli and maintain anergy.  While in 
vitro DCs can repress BCR signaling in B cells of a varied repertoire, in vivo the DCs 
may only regulate B cells that can maintain a prolonged interaction through BCR 
engagement of self-antigen.  In order to study the duration and nature of the interaction 
between autoreactive B cells and DCs in vivo, we would utilize two-photon microscopy 
imaging studies as in Qi et al. (167).  The surface antigen may not be directly responsible 
for repression; however, it could be influencing what B cells are being affected by the 
regulation by promoting colocalization with autoreactive cells. 
 
Antigen plays an important role in the maintenance of B cell tolerance to both adaptive 
and innate stimulation.  Constant BCR occupancy is required to maintain anergy in 
response to further stimulation (136).  During the innate response, antigen stimulation of 
HEL-specific B cells results in unresponsiveness to TLR9 and 4 stimulation.  
Additionally, chronic antigen experience is necessary for LPS-stimulated, autoreactive B 
cells to be susceptible to repression by soluble mediators (103, 104, 220, 226).  These 
data demonstrate that engagement of the BCR modulates the B cell response to other 
stimuli in order to maintain tolerance.  Therefore, we investigated the source of tolerizing 
antigen for low-affinity Sm-specific B cells.  We demonstrated that high-affinity soluble 
antigen, HEL, was sufficient in repressing LPS-induced Ig secretion by HEL-specific B 
cells.  However, Sm-specific B cells were unaffected by treatment with their cognate 
soluble antigens (Figure 3.1).  Further, the antigen on the surface of DCs was not 
important in contact-depedent repression of LPS-induced Ig secretion (Figure 3.7).  
However, during the innate response, chronic antigen experience is necessary to be 
 97
sensitive to repression by soluble factors (103).  Therefore, we propose that surface self-
antigen provides a source of antigen that can engage the BCR without activating the cell.  
This engagement of the BCR causes reprogramming of cell signaling that confers 
susceptibility for IL-6 and CD40L-mediated tolerance, while the DC/MΦs that secrete 
these factors negatively regulate BCR-mediated signal transduction.   
 
We demonstrated that apoptotic cells, which display nuclear self-antigen on their surface, 
enhanced LPS-stimulation of Sm-specific B cells (Figure 3.1).  In lupus-prone mice, an 
accumulation of apoptotic cells leads to activation of autoreactive B cells to produce 
autoantibody (13, 15).  Further, some SLE patients have elevated levels of apoptotic cells 
(16, 17).  Previously, it was shown in the HEL system that antigen-experienced 
autoreactive B cells can be eliminated in a Fas-dependent manner when they encounter T 
cell help; however, they may be protected from apoptosis by interacting with highly 
cross-linking antigen (253, 254).  Thus, an increase in stimulatory form of self-antigen on 
apoptotic cells could contribute to a loss of tolerance.  Further, we have evidence that 
CD11c  splenocytes and BMDCs from MRL/lpr display + four-fold (p<0.0001) and nine-
fold (p=0.001) more Sm compared to B6 DCs, respectively (Carnathan DG unpublished 
observations).  This increase in surface antigen on DCs could contribute to the defect in 
the DC-mediated repression of autoreactive B cells, or it may provide more stimulatory 
antigen to lupus-prone, autoreactive B cells protecting them from Fas-dependent 
apoptosis.  Further experiments to investigate the role for increased surface-antigen in 
defective tolerance mechanisms are necessary. Our data corroborate previous studies 
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demonstrating that the form of antigen is important in the regulation of autoreactive B 
cells. 
 
Our data focus on DC repression of the innate and adaptive immune response and their 
dysregulation in lupus-prone mice.  Previously, we examined the ability of MΦs to 
repress Ig secretion by antigen-experienced autoreactive B cells in response to LPS 
sitmulation (104).  This study demonstrates that much like DCs, MΦs from lupus-prone 
mice are also defective in their secretion of soluble factors and deficient in the ability to 
repress autorective B cells. These cells are defective in their production of the soluble 
repressors IL-6 and CD40L.  Several reports have indicated that DCs and B cells are able 
to interact; however, our study introduces the concept of nuclear self-antigen on the 
surface of MΦs playing a role in regulating B cells through direct contact, demonstrated 
by BCR destabilization that was evident when Sm-specific B cells were purified with by 
DC/MΦs (Figure 3.2, 3.3, and 3.8).  It is of interest to confirm that, like DCs, MΦs are 
also capable of repressing BCR-mediated signal transduction and Ig secretion.   In our 
previous studies of DC/MΦ regulation of autoreactive B cells, it was determined that FO 
B cell LPS-induced Ig secretion can be repressed by both MΦs and DCs while MZ B 
cells are only susceptible to suppression by MΦs (104).  It would be of interest to study 
how the MΦs differentially regulate B cell subset signaling and autoantibody secretion 
compared to DCs.  Determining the role of MΦs in the repression of B cell responses will 
help us to understand how they contribute to tolerance. 
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We have demonstrated that DC/MΦs are capable of regulating both the innate and 
adaptive immune responses by B cells.  We propose a model in which the antigen 
displayed on the surface of these cells might act to colocalize the DC/MΦs with 
autoreactive B cells and induces receptor destabilization. The combination of 
destabilization and the ability of DCs to repress BCR signaling results in anergy.  In vivo, 
autoreactive cells are subject to continuous ligation of the BCR with self-antigen, which 
may cause the B cell to reprogram their response to IL-6, CD40L, and TNF-α secreted by 
DC/MΦs upon LPS stimulation resulting in their repression. These cytokines are 
sufficient to regulate Ig secretion of LPS-stimulated autoreactive B cells; however, a DC 
mediated contact-dependent mechanism is utilized if the DC is not activated or is 
defective in secretion of repressive factors.  In MRL/lpr mice, the defective DCs fail to 
secrete the soluble mediators and display abnormal amounts of surface self-antigen; their 
dysregulation results in their inability to repress autoreactive B cell Ig secretion.  Thus, 
DC/MΦ-regulation of adaptive and innate responses is essential in maintaining tolerance 
and preventing autoimmunity. 
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